boston scientific corporation and subsidiariesconsolidated statements of operations year ended december 31in millions except per share data201520142013    net sales747773807143cost of products sold217322102174gross profit530451704969    operating expenses   selling general and administrative expenses287329022674research and development expenses876817861royalty expense70111140amortization expense495438410goodwill impairment charges423intangible asset impairment charges1919553contingent consideration expense benefit123854restructuring charges2669101litigationrelated charges11051036221pension termination charges44gain on divestiture1238 563154714849operating income loss 327301120    other income expense   interest expense284216324other net39819 income loss before income taxes650509223income tax benefit expense411390102net income loss239119121    net income loss per common share  basic018009009net income loss per common share  assuming dilution018009009    weightedaverage shares outstanding   basic134121324313412assuming dilution134121324313412see notes to the consolidated financial statements 59boston scientific corporation and subsidiariesconsolidated statements of comprehensive income loss   year ended december 31in millions 2015 2014 2013net income loss 239 119 121other comprehensive income loss      foreign currency translation adjustment 16 22 10net change in unrealized gains and losses on derivative financial instruments net of tax 67 78 107net change in unrealized costs associated with certain retirement plans 27 18 22total other comprehensive income loss 56 38 139total comprehensive income loss 295 81 18see notes to the consolidated financial statements 60boston scientific corporation and subsidiariesconsolidated balance sheets as of december 31in millions except share and per share data2015 2014   restatedassets   current assets   cash and cash equivalents319 587trade accounts receivable net1275 1183inventories1016 946deferred and prepaid income taxes496 447other current assets365 443total current assets3471 3606property plant and equipment net1490 1507goodwill6473 5898other intangible assets net6194 5606other longterm assets505 407total assets18133 17024    liabilities and stockholders equity   current liabilities   current debt obligations3 403accounts payable209 262accrued expenses1970 1950other current liabilities248 231total current liabilities2430 2846longterm debt5674 3841deferred income taxes735 1214other longterm liabilities2974 2666    commitments and contingencies     stockholders equity   preferred stock 001 par value  authorized 50000000 shares none issued and outstanding common stock 001 par value  authorized 2000000000 shares issued 1594213786 shares as of december 31 2015 and 1575018236 shares as of december 31 2014 16 16treasury stock at cost  247566270 shares as of december 31 2015 and 247566270 shares as of december 31 20141717 1717additional paidin capital16860 16703accumulated deficit8927 8689accumulated other comprehensive income loss net of tax   foreign currency translation adjustment54 38unrealized gain on derivative financial instruments152 219unrealized costs associated with certain retirement plans10 37total stockholders equity6320 6457total liabilities and stockholders equity18133 17024see notes to the consolidated financial statementscertain prior year balances related to debt issuance costs have been restated to reflect our adoption of accounting standards codification update no 201503 interestimputation of interest subtopic 83530 simplifying the presentation of debt issuance costs amounts reclassified from other longterm assets to longterm debt were not material please refer to note a  significant accounting policies and note q  new accounting pronouncements for additional details  61boston scientific corporation and subsidiariesconsolidated statements of stockholders equity            accumulated        additional   other  common stock treasury paidin accumulated comprehensivein millions except share data shares issued par value stock capital deficit income lossbalance as of december 31 2012 1542347188 15 1092 16429 8449 33net loss         121  changes in other comprehensive income loss net of tax            foreign currency translation adjustment           10net change in derivative financial instruments           107net change in certain retirement plans           22impact of stockbased compensation plans net of tax 17955446 1   150    acquisition of treasury stock     500      balance as of december 31 2013 1560302634 16 1592 16579 8570 106net loss         119  changes in other comprehensive income loss net of tax            foreign currency translation adjustment           22net change in derivative financial instruments           78net change in certain retirement plans           18impact of stockbased compensation plans net of tax 14715602   124    acquisition of treasury stock     125      balance as of december 31 2014 1575018236 16 1717 16703 8689 144             net loss         239  changes in other comprehensive income loss net of tax            foreign currency translation adjustment           16net change in derivative financial instruments           67net change in certain retirement plans           27impact of stockbased compensation plans net of tax 19195550   157    rounding        1  balance as of december 31 2015 1594213786 16 1717 16860 8927 88see notes to the consolidated financial statements 62boston scientific corporation and subsidiariesconsolidated statements of cash flows  year ended december 31in millions201520142013operating activities   net income loss 239119121adjustments to reconcile net income loss to cash provided by operating activities   gain on sale of businesses1238depreciation and amortization769725689deferred and prepaid income taxes532397223stockbased compensation expense107103105goodwill impairment charges423intangible asset impairment charges1919553net losses gains on investments and notes receivable9279contingent consideration expense benefit123854payment of contingent consideration in excess of amounts established in purchase accounting571035pension termination charges44inventory stepup amortization369other net411831increase decrease in cash flows from operating assets and liabilities   trade accounts receivable1753101inventories3817other assets233391accounts payable and accrued expenses206209other liabilities337403209cash provided by operating activities60012691110    investing activities   purchases of property plant and equipment247259245proceeds on disposals of property plant and equipment53payments for acquisitions of businesses net of cash acquired1734486274proceeds from business divestitures net of costs1230payments for investments and acquisitions of certain technologies2662644proceeds from investments and collections of notes receivable61145cash used for investing activities2186745475    financing activities   payments of contingent consideration amounts previously established in purchase accounting15634160proceeds from longterm borrowings net of debt issuance costs25801440payments on longterm borrowings11501450proceeds from borrowings on credit facilities565810340payments on borrowings from credit facilities565810340payments for acquisitions of treasury stock125500cash used to net share settle employee equity awards665128proceeds from issuances of shares of common stock1146074cash provided by used for financing activities1322150624    effect of foreign exchange rates on cash441    net increase decrease in cash and cash equivalents26837010cash and cash equivalents at beginning of period587217207cash and cash equivalents at end of period319587217    supplemental information   cash paid for income taxes net807467cash paid for interest283221329fair value of contingent consideration recorded in purchase accounting633 see notes to the consolidated financial statements 63notes to the consolidated financial statementsnote a  significant accounting policiesprinciples of consolidationour consolidated financial statements include the accounts of boston scientific corporation and our whollyowned subsidiaries after the elimination of intercompany transactions we assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity vie for any vies we perform an analysis to determine whether our variable interests give us a controlling financial interest in a vie the analysis identifies the primary beneficiary of a vie as the enterprise that has both 1 the power to direct activities of a vie that most significantly impact the entitys economic performance and 2 the obligation to absorb losses of the entity or the right to receive benefits from the entity based on our assessments under the applicable guidance we did not have controlling financial or operating interests in any vies and therefore did not consolidate any vies during the years ended december 31 2015 2014 and 2013on january 3 2011 we closed the sale of our neurovascular business to stryker corporation stryker due to our continuing involvement in the operations of the neurovascular business following the divestiture the divestiture did not meet the criteria for presentation as a discontinued operation and therefore the results of the neurovascular business are included in our results of operations for all periods presented refer to note c  divestitures for a description of this business divestiturebasis of presentationthe accompanying consolidated financial statements of boston scientific corporation have been prepared in accordance with accounting principles generally accepted in the united states us gaap and with the instructions to form 10k and regulation sxadditionally certain prior year balances related to debt issuance costs have been restated to reflect our adoption of accounting standards codification update no 201503 interestimputation of interest subtopic 83530 simplifying the presentation of debt issuance costs amounts reclassified from other longterm assets to longterm debt were not material refer to note q  new accounting pronouncements for additional information on our adoption of the accounting pronouncement subsequent eventswe evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our financial statements on january 29 2016 following a ruling by the maryland court of special appeals related to litigation with mirowski family ventures llc we increased our accrual related to this matter this is considered a material recognized subsequent event and has been reflected appropriately in our accompanying consolidated financial statements see note k  commitments and contingencies for further details in addition those items requiring disclosure unrecognized subsequent events in the financial statements have been disclosed accordingly see note k commitments and contingencies for further detailsaccounting estimatesto prepare our consolidated financial statements in accordance with us gaap management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities the disclosure of contingent liabilities as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting period our actual results may differ from these estimates refer to critical accounting estimates included in item 7 of this annual report for further discussioncash and cash equivalentswe record cash and cash equivalents in our consolidated balance sheets at cost which approximates fair value our policy is to invest excess cash in shortterm marketable securities earning a market rate of interest without assuming undue risk to principal and we limit our direct exposure to securities in any one industry or issuer we consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalentswe record availableforsale investments at fair value and exclude unrealized gains and temporary losses on availableforsale securities from earnings reporting such gains and losses net of tax as a separate component of stockholders equity until realized we compute realized gains and losses on sales of availableforsale securities based on the average cost method adjusted for any otherthantemporary declines in fair value we held no availableforsale securities during 2015 2014 and 2013  64concentrations of credit riskfinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents derivative financial instrument contracts and accounts and notes receivable our investment policy limits exposure to concentrations of credit risk and changes in market conditions counterparties to financial instruments expose us to creditrelated losses in the event of nonperformance we transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure we provide credit in the normal course of business to hospitals healthcare agencies clinics doctors offices and other private and governmental institutions and generally do not require collateral we record our accounts receivable in our consolidated balance sheets at net realizable value we perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses based on historical information and managements best estimates amounts determined to be uncollectible are written off against this reserve we recorded writeoffs of uncollectible accounts receivable of 16 million in 2015 15 million in 2014 and 12 million in 2013 we are not dependent on any single institution and no single customer accounted for more than ten percent of our net sales in 2015 2014 and 2013 or accounts receivable at december 31 2015 or 2014 however large group purchasing organizations hospital networks and other buying groups have become increasingly important to our business and represent a substantial portion of our us net saleswe closely monitor outstanding receivables for potential collection risks including those that may arise from economic conditions in both the us and international economies our european sales to governmentowned or supported customers in southern europe specifically greece italy spain and portugal are subject to an increased number of days outstanding relative to other countries prior to payment historically receivable balances with certain publiclyowned hospitals in these countries accumulate over a period of time and are then subsequently settled as large lump sum payments while we believe our allowance for doubtful accounts in these countries is adequate as of december 31 2015 if significant changes were to occur in the payment practices of these european governments or if government funding becomes unavailable we may not be able to collect on receivables due to us from these customers and our writeoffs of uncollectible amounts may increase  revenue recognitionwe generate revenue primarily from the sale of singleuse medical devices and present revenue net of sales taxes in our consolidated statements of operations we sell our products primarily through a direct sales force in certain international markets we sell our products through independent distributors we consider revenue to be realized or realizable and earned when all of the following criteria are met persuasive evidence of a sales arrangement exists delivery has occurred or services have been rendered the price is fixed or determinable and collectibility is reasonably assured revenue is recognized upon passage of title and risk of loss to customers unless we are required to provide additional services and provided we can form an estimate for sales returns we recognize revenue from consignment arrangements based on product usage or implant which indicates that the sale is complete for revenue arrangements with multiple deliverables where the sale of a device is combined with a future service obligation we defer revenue on the undelivered element and recognize this revenue over the related service period many of our cardiac rhythm management crm product offerings combine the sale of a device with our latitude patient management system which represents a future service obligation generally we do not have vendor specific objective evidence of selling price available related to our future service obligations therefore we determine our estimates of selling price using third party evidence when available otherwise we use our best estimate of selling price we allocate arrangement consideration using the relative selling price method we generally allow our customers to return defective damaged and in certain cases expired products for credit we base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product in addition we may allow customers to return previously purchased products for nextgeneration product offerings for these transactions we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the nextgeneration products are shipped to the customerwe also offer sales rebates and discounts to certain customers we treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current we estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates if we are unable to estimate the expected rebates reasonably we record a liability for the maximum rebate percentage offered we have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices we recognize revenue from these agreements following the same revenue recognition criteria discussed above 65warranty obligationswe offer warranties on certain of our product offerings the majority of our warranty liability relates to implantable devices offered by our crm business which include defibrillator and pacemaker systems our crm products come with a standard limited warranty covering the replacement of these devices we offer a full warranty for a portion of the period postimplant and a partial warranty for a period of time thereafter we estimate the costs that we may incur under our warranty programs based on the number of units sold historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs we assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessarychanges in our product warranty accrual during 2015 2014 and 2013 consisted of the following in millions   year ended december 31  2015 2014 2013beginning balance 25 28 26provision 15 9 12settlements reversals 17 12 10ending balance 23 25 28inventorieswe state inventories at the lower of firstin firstout cost or market we base our provisions for excess expired and obsolete inventory primarily on our estimates of forecasted net sales a significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess expired and obsolete inventory in the future further the industry in which we participate is characterized by rapid product development and frequent new product introductions uncertain timing of nextgeneration product approvals variability in product launch strategies product recalls and variation in product utilization all affect our estimates related to excess expired and obsolete inventory approximately 40 percent of our finished goods inventory as of december 31 2015 and december 31 2014 was at customer locations pursuant to consignment arrangements or held by sales representativesproperty plant and equipmentwe state property plant equipment and leasehold improvements at historical cost we charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset we provide for depreciation using the straightline method at rates that approximate the estimated useful lives of the assets we depreciate buildings and improvements over a 20 to 40 year life equipment furniture and fixtures over a three to ten year life and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease depreciation expense was 274 million in 2015 287 million in 2014 and 279 million in 2013valuation of business combinationswe allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the dates of acquisition including identifiable intangible assets and inprocess research and development which either arise from a contractual or legal right or are separable from goodwill we base the fair value of identifiable intangible assets acquired in a business combination including inprocess research and development on detailed valuations that use information and assumptions provided by management which consider managements best estimates of inputs and assumptions that a market participant would use we allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired to goodwill transaction costs associated with these acquisitions are expensed as incurred through selling general and administrative costsin those circumstances where an acquisition involves a contingent consideration arrangement we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date we remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving regulatory revenue or commercializationbased milestones  66indefinitelived intangibles including inprocess research and developmentour indefinitelived intangible assets that are not subject to amortization include acquired balloon and other technology which is foundational to our continuing operations within the cardiovascular market and other markets within interventional medicine and inprocess research and development intangible assets acquired in a business combination our inprocess research and development represents intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility regardless of whether they have alternative future use the primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region we classify inprocess research and development acquired in a business combination as an indefinitelived intangible asset until the completion or abandonment of the associated research and development efforts upon completion of the associated research and development efforts we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives upon permanent abandonment we would writeoff the remaining carrying amount of the associated inprocess research and development intangible asset we test our indefinitelived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinitelived assets in addition we review our indefinitelived assets for classification and impairment more frequently if changes in circumstances or indicators exist we assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinitelived intangible assets are impaired if we conclude that it is more likely than not that the asset is impaired we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with asc topic 350 intangiblesgoodwill and other if the carrying value exceeds the fair value of the indefinitelived intangible asset we write the carrying value down to the fair valuewe use the income approach to determine the fair values of our inprocess research and development this approach calculates fair value by estimating the aftertax cash flows attributable to an inprocess project over its useful life and then discounting these aftertax cash flows back to a present value we base our revenue assumptions on estimates of relevant market sizes expected market growth rates expected trends in technology and expected levels of market share in arriving at the value of the inprocess projects we consider among other factors the inprocess projects stage of completion the complexity of the work completed as of the acquisition date the costs already incurred the projected costs to complete the contribution of other acquired assets the expected regulatory path and introduction dates by region and the estimated useful life of the technology we apply a marketparticipant riskadjusted discount rate to arrive at a present value as of the date of acquisition see note d  goodwill and other intangible assets for more information related to indefinitelived intangibles including inprocess research and development during 2015 2014 and 2013for asset purchases outside of business combinations we expense any purchased research and development assets as of the acquisition date amortization and impairment of intangible assetswe record intangible assets at historical cost and amortize them over their estimated useful lives we use a straightline method of amortization unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined the approximate useful lives for amortization of our intangible assets are as follows patents and licenses two to 20 years definitelived technologyrelated five to 25 years customer relationships five to 25 years other intangible assets variouswe review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life conditions that may indicate impairment include but are not limited to a significant adverse change in legal factors or business climate that could affect the value of an asset a product recall or an adverse action or assessment by a regulator if an impairment indicator exists we test the intangible asset for recoverability for purposes of the recoverability test we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities if the carrying value of the intangible asset asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset asset group we will write the carrying value down to the fair value in the period identified we calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a riskadjusted discount rate in determining our estimated future cash flows associated with our intangible assets we use estimates and assumptions about future revenue contributions cost structures and remaining useful lives of the asset asset  67group see note d  goodwill and other intangible assets for more information related to impairments of intangible assets during 2015 2014 and 2013for patents developed internally we capitalize costs incurred to obtain patents including attorney fees registration fees consulting fees and other expenditures directly related to securing the patent goodwill valuationeffective as of january 1 2013 we reorganized our business from geographic regions to fully operationalized global business units our reorganization changed our reporting structure and changed the composition of our reporting units for goodwill impairment testing purposes following the reorganization based on information regularly reviewed by our chief operating decision maker we have three new global reportable segments consisting of cardiovascular rhythm management and medsurg we determined our new global reporting units by identifying our operating segments and assessing whether any components of these segments constituted a business for which discrete financial information is available and whether segment management regularly reviews the operating results of any components through this process we identified the following global reporting units as of january 1 2013 interventional cardiology peripheral interventions cardiac rhythm management electrophysiology endoscopy urology and pelvic health and neuromodulation we allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill we test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist in performing the assessment we utilize the twostep approach prescribed under asc topic 350 intangiblesgoodwill and other topic 350 the first step requires a comparison of the carrying value of the reporting units as defined to the fair value of these units we assess goodwill for impairment at the reporting unit level which is defined as an operating segment or one level below an operating segment referred to as a component we determine our reporting units by first identifying our operating segments and then assess whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component we aggregate components within an operating segment that have similar economic characteristics for our 2015 2014 and 2013 annual impairment assessment we identified seven reporting units including interventional cardiology peripheral interventions cardiac rhythm management electrophysiology endoscopy urology and pelvic health and neuromodulation when allocating goodwill from business combinations to our reporting units we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition in addition for purposes of performing our goodwill impairment tests assets and liabilities including corporate assets which relate to a reporting units operations and would be considered in determining its fair value are allocated to the individual reporting units we allocate assets and liabilities not directly related to a specific reporting unit but from which the reporting unit benefits based primarily on the respective revenue contribution of each reporting unitduring 2015 2014 and 2013 we used only the income approach specifically the discounted cash flow dcf method to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments this approach calculates fair value by estimating the aftertax cash flows attributable to a reporting unit and then discounting these aftertax cash flows to a present value using a riskadjusted discount rate we selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets we have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technologybased assets within our reporting units for application of the cost approach therefore we believe that the income approach represents the most appropriate valuation technique for which sufficient data are available to determine the fair value of our reporting unitsin applying the income approach to our accounting for goodwill we make assumptions about the amount and timing of future expected cash flows terminal value growth rates and appropriate discount rates the amount and timing of future cash flows within our dcf analysis is based on our most recent operational budgets long range strategic plans and other estimates the terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in our dcf analysis and reflects our best estimates for stable perpetual growth of our reporting units we use estimates of marketparticipant riskadjusted weighted average cost of capital wacc as a basis for determining the discount rates to apply to our reporting units future expected cash flowsif the carrying value of a reporting unit exceeds its fair value we then perform the second step of the goodwill impairment test to measure the amount of impairment loss if any if the carrying value of a reporting unit is zero or negative we evaluate whether  68it is more likely than not that a goodwill impairment exists if we determine adverse qualitative factors exist that would indicate it is more likely than not an impairment exists we then perform the second step of the goodwill test the second step of the goodwill impairment test compares the estimated fair value of a reporting units goodwill to its carrying value if we were unable to complete the second step of the test prior to the issuance of our financial statements and an impairment loss was probable and could be reasonably estimated we would recognize our best estimate of the loss in our current period financial statements and disclose that the amount is an estimate we would then recognize any adjustment to that estimate in subsequent reporting periods once we have finalized the second step of the impairment test see note d  goodwill and other intangible assets for discussion of our goodwill impairment chargesinvestments in publicly traded and privately held entitieswe account for our publicly traded investments as availableforsale securities based on the quoted market price at the end of the reporting period we compute realized gains and losses on sales of availableforsale securities based on the average cost method adjusted for any otherthantemporary declines in fair value we held no availableforsale securities during 2015 2014 and 2013 we account for investments in entities over which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a vie in which we are the primary beneficiary in accordance with asc topic 323 investments  equity method and joint ventures we record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee including all adjustments similar to those made in preparing consolidated financial statements we account for investments in entities in which we have less than a 20 percent ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee in accordance with asc topic 325 investments  other in addition we have notes receivable from certain companies that we account for in accordance with asc topic 320 investments  debt and equity securities refer to note b  acquisitions and strategic investments for additional details on the balances of our equity and cost method investmentseach reporting period we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment examples of such impairment indicators include but are not limited to a significant deterioration in earnings performance recent financing rounds at reduced valuations a significant adverse change in the regulatory economic or technological environment of an investee or a significant doubt about an investees ability to continue as a going concern if we identify an impairment indicator we will estimate the fair value of the investment and compare it to its carrying value our estimation of fair value considers all available financial information related to the investee including valuations based on recent thirdparty equity investments in the investee if the fair value of the investment is less than its carrying value the investment is impaired and we make a determination as to whether the impairment is otherthantemporary we deem an impairment to be otherthantemporary unless we have the ability and intent to hold an investment for a period sufficient for a market recovery up to the carrying value of the investment further evidence must indicate that the carrying value of the investment is recoverable within a reasonable period for otherthantemporary impairments we recognize an impairment loss equal to the difference between an investments carrying value and its fair value impairment losses on our investments are included in other net in our consolidated statements of operationsincome taxeswe utilize the asset and liability method of accounting for income taxes under this method we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities we measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse we reduce our deferred tax assets by a valuation allowance if based upon the weight of available evidence it is more likely than not that we will not realize some portion or all of the deferred tax assets we consider relevant evidence both positive and negative to determine the need for a valuation allowance information evaluated includes our financial position and results of operations for the current and preceding years the availability of deferred tax liabilities and tax carrybacks as well as an evaluation of currently available information about future yearswe have not provided us income taxes and foreign withholding taxes on the undistributed earnings of foreign subsidiaries as of december 31 2015 because we intend to permanently reinvest such earnings outside the us as of december 31 2015 the cumulative amount of excess financial reporting basis over the tax basis of investments in foreign subsidiaries that is indefinitely reinvested is approximately 89 billion generally such amounts become subject to us taxation upon the remittance of dividends and under certain other circumstances it is not practicable to estimate the amount of deferred tax liability related to investments in these foreign subsidiarieswe provide for potential amounts due in various tax jurisdictions in the ordinary course of conducting business in multiple countries and tax jurisdictions there are many transactions and calculations where the ultimate tax outcome is uncertain therefore judgment is required based on individual facts circumstances and information available in determining whether or not based on  69technical merits the position will be sustained upon examination in our opinion we have made adequate provisions for income taxes in determining our worldwide income tax position for all years subject to audit although we believe our estimates are reasonable the final outcome of open tax matters may be different from that which we have reflected in our historical income tax provisions and accruals such differences could have a material impact on our income tax provision and operating results see note j  income taxes for further information and discussion of our income tax provision and balanceslegal and product liability costsin the normal course of business we are involved in various legal and regulatory proceedings including intellectual property breach of contract securities litigation and product liability suits in some cases the claimants seek damages as well as other relief which if granted could require significant expenditures or impact our ability to sell our products we are also the subject of certain governmental investigations which could result in substantial fines penalties and administrative remedies we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims we accrue anticipated costs of settlement damages losses for product liability claims and under certain conditions costs of defense based on historical experience or to the extent specific losses are probable and estimable otherwise we expense these costs as incurred if the estimate of a probable loss is a range and no amount within the range is more likely we accrue the minimum amount of the range we analyze litigation settlements to identify each element of the arrangement we allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit see note k  commitments and contingencies for discussion of our individual material legal proceedingscosts associated with exit activitieswe record employee termination costs in accordance with asc topic 712 compensation  nonretirement and postemployment benefits if we pay the benefits as part of an ongoing benefit arrangement which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements we accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered the rights to the benefits have vested the payment is probable and we can reasonably estimate the liability we account for employee termination benefits that represent a onetime benefit in accordance with asc topic 420 exit or disposal cost obligations we record such costs into expense over the employees future service period if any other costs associated with exit activities may include contract termination costs including costs related to leased facilities to be abandoned or subleased consultant fees and impairments of longlived assets the costs are expensed in accordance with asc topic 420 and asc topic 360 property plant and equipment and are included in restructuring charges in our consolidated statement of operations additionally costs directly related to our active restructuring initiatives including program management costs accelerated depreciation and costs to transfer product lines among facilities are included within costs of products sold and selling general and administrative expenses in our consolidated statement of operations see note h  restructuringrelated activities for further information and discussion of our restructuring planstranslation of foreign currencywe translate all assets and liabilities of foreign subsidiaries from local currency into us dollars using the yearend exchange rate and translate revenues and expenses at the average exchange rates in effect during the year we show the net effect of these translation adjustments in our consolidated financial statements as a component of accumulated other comprehensive income for any significant foreign subsidiaries located in highly inflationary economies we would remeasure their financial statements as if the functional currency were the us dollar we did not record any highly inflationary economy translation adjustments in 2015 2014 or 2013foreign currency transaction gains and losses are included in other net in our consolidated statements of operations net of losses and gains from any related derivative financial instruments we recognized net foreign currency transaction losses of 21 million in 2015 18 million in 2014 and 11 million in 2013financial instrumentswe recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with asc topic 815 derivatives and hedging and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements in accordance with topic 815 for those derivative instruments that are designated and qualify as hedging instruments the hedging instrument must be designated based upon the exposure being hedged as a fair value hedge cash flow hedge or a hedge of a net investment in a foreign operation the accounting for changes in the fair value ie  70gains or losses of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further on the type of hedging relationship our derivative instruments do not subject our earnings or cash flows to material risk as gains and losses on these derivatives generally offset losses and gains on the item being hedged we do not enter into derivative transactions for speculative purposes and we do not have any nonderivative instruments that are designated as hedging instruments pursuant to topic 815 refer to note e  fair value measurements for more information on our derivative instrumentsshipping and handling costswe generally do not bill customers for shipping and handling of our products shipping and handling costs of 93 million in 2015 100 million in 2014 and 97 million in 2013 are included in selling general and administrative expenses in the accompanying consolidated statements of operationsresearch and developmentwe expense research and development costs including new product development programs regulatory compliance and clinical research as incurred refer to indefinitelived intangibles including inprocess research and development for our policy regarding inprocess research and development acquired in connection with our business combinations and asset purchasesemployee retirement plansfollowing our 2006 acquisition of guidant corporation we sponsored the guidant retirement plan a frozen noncontributory defined benefit plan covering a select group of current and former employees the plan was partially frozen as of september 25 1995 and completely frozen as of may 31 2007 and was terminated effective december 1 2014 during 2015 we finalized the termination process and settled the plans obligations as a result we recorded pension termination charges of 44 million for the year ended december 31 2015we continue to sponsor the guidant supplemental retirement plan a frozen nonqualified defined benefit plan for certain former officers and employees of guidant the guidant supplemental retirement plan was partially funded through a rabbi trust that contains segregated company assets used to pay the benefit obligations related to the plan we also maintain an executive retirement plan a defined benefit plan covering executive officers and division presidents and certain persons that may have served in these roles participants may retire with unreduced benefits once retirement conditions have been satisfied in addition we maintain retirement plans covering certain international employeeswe use a december 31 measurement date for these plans and record the underfunded portion as a liability recognizing changes in the funded status through other comprehensive income oci the outstanding obligation as of december 31 2015 and 2014 is as follows  as of december 31 2015 as of december 31 2014in millions projectedbenefitobligation pbo fair value of plan assets underfundedpbo recognized projectedbenefitobligation pbo fair value of plan assets underfundedpbo recognizedexecutive retirement plan 14  14 13  13guidant retirement plan frozen    148 140 8guidant supplemental retirement plan frozen 33  33 34  34international retirement plans 84 52 32 90 51 39  131 52 79 285 191 94the value of the rabbi trust assets used to pay the guidant supplemental retirement plan benefits included in our accompanying consolidated financial statements was approximately 11 million as of december 31 2015 and 14 million as of december 31 2014 71the critical assumptions associated with our employee retirement plans as of december 31 2015 are as follows   expected returnon plan assets rate of discountrate  compensationincreaseexecutive retirement plan375   300guidant supplemental retirement plan frozen425    international retirement plans100  220 300  410 300  678we base our discount rate on the rates of return available on highquality bonds with maturities approximating the expected period over which benefits will be paid the rate of compensation increase is based on historical and expected rate increases we base our rate of expected return on plan assets on historical experience our investment guidelines and expectations for longterm rates of returna rollforward of the changes in the fair value of plan assets for our funded retirement plans during 2015 and 2014 is as follows  year ended december 31in millions 2015 2014beginning fair value 191 166actual return on plan assets 1 26employer contributions 6 16benefits paid 145 11net transfers in out  foreign currency exchange 1 6ending fair value 52 191we also sponsor a voluntary 401k retirement savings plan for eligible employees we match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent but not exceeding six percent of employee eligible compensation total expense for our matching contributions to the plan was 69 million in 2015 63 million in 2014 and 59 million in 2013net income loss per common sharewe base net income loss per common share upon the weightedaverage number of common shares and common stock equivalents outstanding during each year potential common stock equivalents are determined using the treasury stock method we exclude stock options whose effect would be antidilutive from the calculationnote b  acquisitions and strategic investmentsour consolidated financial statements include the operating results for each acquired entity from its respective date of acquisition we do not present pro forma financial information for these acquisitions given their results are not material to our consolidated financial statements transaction costs associated with these acquisitions were expensed as incurred and are not material for the years ended december 31 2015 2014 and 20132015 acquisitionsinterventional radiology business of celonova bioscienceson december 31 2015 we completed the acquisition of the interventional radiology business of celonova biosciences celonova for an upfront payment of 70 million and additional payments contingent on regulatory and sales milestones the acquisition includes drugeluting microspheres designed to be loaded with chemotherapy drugs for delivery to cancerous tumors and spherical embolic products used to treat uterine fibroids and other conditions we are in the process of integrating celonova into our peripheral interventions business 72ams portfolio acquisitionon august 3 2015 we completed the acquisition of the american medical systems male urology portfolio ams portfolio acquisition which includes the mens health and prostate health businesses from endo international plc total consideration was comprised of 1616 billion in upfront cash plus related fees and expenses and a potential additional 50 million in consideration based on 2016 sales the ams male urology portfolio is being integrated with our formerly named urology and womens health business and the joint businesses have become urology and pelvic health in addition as part of the acquisition agreement we made a 60 million series b nonvoting preferred stock investment in the womens health business of endo health solutions a wholly owned subsidiary of endo international plc representing the remaining womens health business of the american medical systems portfolio this investment was subsequently repaid in the fourth quarter of 2015xlumena incon april 2 2015 we acquired xlumena inc xlumena a medical device company that developed minimally invasive devices for endoscopic ultrasound eus guided transluminal drainage of targeted areas within the gastrointestinal tract the purchase agreement called for an upfront payment of 63 million an additional payment of 13 million upon fda clearance of the hot axios product and further salesbased milestones based on sales achieved through 2018 we are in the process of integrating xlumena into our endoscopy business and expect the integration to be substantially complete by the end of 2016in addition we completed other acquisitions during 2015 for total consideration of 6 million in cash at closing plus contingent consideration of up to 1 million purchase price allocationwe accounted for these acquisitions as business combinations and in accordance with financial accounting standards board fasb accounting standards codification asc topic 805 business combinations we have recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates the components of the aggregate preliminary purchase prices are as follows in millionscash net of cash acquired1734fair value of contingent consideration63 1797the following summarizes the aggregate preliminary purchase price allocation for the 2015 acquisitions as of december 31 2015 in millionsgoodwill573amortizable intangible assets1073indefinitelived intangible assets7inventory103property plant and equipment43other net assets43deferred income taxes45 1797 73we allocated a portion of the preliminary purchase price to specific intangible asset categories as follows amountassignedin millions weightedaverageamortizationperiodin years range of riskadjusted discountrates used inpurchase priceallocationamortizable intangible assets     technologyrelated431 1113 135  23customer relationships624 1213 135  15other intangible assets18 13 135indefinitelived intangible assets     inprocess research amp development7 na 17 1080    2014 acquisitionsinterventional business of bayer agon august 29 2014 we completed the acquisition of the interventional division of bayer ag bayer for a total cash consideration of 414 million we believe that this acquisition enhances our ability to offer physicians and healthcare systems a more complete portfolio of solutions to treat challenging vascular conditions the transaction includes the angiojet thrombectomy system and the fetch 2 aspiration catheter which are used in endovascular procedures to remove blood clots from blocked arteries and veins and the jetstream atherectomy system used to remove plaque and thrombi from diseased arteries we are integrating the operations of the bayer business with our peripheral interventions and interventional cardiology divisions and expect integration to be substantially completed by the middle of 2016iogyn incon may 7 2014 we completed the acquisition of the remaining fully diluted equity of iogyn inc iogyn prior to the acquisition we held a 28 percent minority interest in iogyn in addition to notes receivable of approximately 8 million total consideration was comprised of a net cash payment of 65 million at closing to acquire the remaining 72 percent of iogyn equity and repay outstanding debt iogyn has developed the symphion system a next generation system for hysteroscopic intrauterine tissue removal including fibroids myomas and polyps in march 2014 iogyn received us food amp drug administration fda approval for the system and in october 2014 we began a limited market release of the system in the united states we have integrated the operations of the iogyn business into our urology and pelvic health businessin addition we completed other acquisitions during 2014 for total consideration of 7 million cash at closing plus contingent consideration of up to 4 millionpurchase price allocationwe accounted for these acquisitions as business combinations and in accordance with asc topic 805 business combinations we have recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date the components of the aggregate purchase price for the bayer and iogyn acquisitions are as follows in millionscash net of cash acquired479fair value of prior interests31 510in addition prior to the acquisition of iogyn we had an equity interest in iogyn and held 8 million of notes receivables we remeasured our previouslyheld investments to their estimated acquisitiondate fair value of 31 million and recorded a gain of 19 million in other net in the accompanying consolidated statements of operations during the second quarter of 2014 we measured the fair values of the previouslyheld investments based on the liquidation preferences and priority of the equity interest and debt including accrued interest 74the following summarizes the aggregate purchase price allocation for bayer and iogyn as of december 31 2014goodwill210amortizable intangible assets263inventory23property plant and equipment17prepaid transaction service agreement5other net assets1deferred income taxes7 510we allocated a portion of the purchase price to specific intangible asset categories as follows amountassignedin millions weightedaverageamortizationperiodin years range of riskadjusted discountrates used inpurchase priceallocationamortizable intangible assets     technologyrelated233 10  14 14  18 customer relationships29 10 18other intangible assets1 2 14 263    2013 acquisitionon november 1 2013 we completed the acquisition of the electrophysiology business of cr bard inc bard ep for 274 million in cash this acquisition added a strong commercial team and complementary portfolio of ablation catheters diagnostic tools and electrophysiology recording systems which we believe will allow us to better serve the global electrophysiology market through a more comprehensive portfolio offering and sales infrastructure purchase price allocationwe accounted for this acquisition as a business combination and in accordance with asc topic 805 business combinations we have recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date the following summarizes the aggregate purchase price allocation for the bard ep acquisition in millionsgoodwill140amortizable intangible assets112other net assets19deferred income taxes3 274we allocated a portion of the purchase price to specific intangible asset categories as of the acquisition date as follows amountassignedin millions weightedaverageamortizationperiodin years range of riskadjusted discountrates used inpurchase priceallocationamortizable intangible assets     technologyrelated82 10 115 customer relationships30 7 115 112     75for our 2015 2014 and 2013 acquisitions our technologyrelated intangible assets consist of technical processes intellectual property and institutional understanding with respect to products and processes that we will leverage in future products or processes and will carry forward from one product generation to the next we used the income approach and relief from royalty approach to derive the fair value of the technologyrelated intangible assets and are amortizing them on a straightline basis over their assigned estimated useful livesinprocess research and development represents the estimated fair value of acquired inprocess research and development projects that have not yet reached technological feasibility these indefinitelived intangible assets are tested for impairment on an annual basis or more frequently if impairment indicators are present in accordance with us gaap and our accounting policies upon completion of the associated research and development efforts we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives the primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying productscustomer relationships represent the estimated fair value of noncontractual customer and distributor relationships customer relationships are direct relationships with physicians and hospitals performing procedures with the acquired products and distributor relationships are relationships with third parties used to sell products both as of the acquisition date these relationships were valued separately from goodwill because there is a history and pattern of conducting business with customers and distributors we used the income approach or the replacement cost and lost profits methodology to derive the fair value of the customer relationships the customer relationships intangible assets are amortized on a straightline basis over their assigned estimated useful livesother intangible assets primarily include acquired tradenames these tradenames include brand names that we expect to continue using in our product portfolio and related marketing materials the tradenames are valued using a relief from royalty methodology and are amortized on a straightline basis over their assigned estimated useful liveswe believe that the estimated intangible asset values represent the fair value at the date of acquisition and do not exceed the amount a third party would pay for the assets these fair value measurements are based on significant unobservable inputs including management estimates and assumptions and accordingly are classified as level 3 within the fair value hierarchy prescribed by fasb asc topic 820 fair value measurements and disclosureswe recorded the excess of the aggregate purchase price over the estimated fair values of the identifiable assets acquired as goodwill goodwill was established due primarily to synergies expected to be gained from leveraging our existing operations as well as revenue and cash flow projections associated with future technologies and has been allocated to our reportable segments based on the relative expected benefit of the goodwill recorded approximately 453 million related to our 2015 acquisitions is deductible for tax purposes of the goodwill recorded related to our 2014 and 2013 acquisitions 160 million and 131 million respectively is deductible for tax purposes see note d  goodwill and other intangible assets for more information related to goodwill allocated to our reportable segmentscontingent considerationcertain of our acquisitions involve contingent consideration arrangements payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones including attaining specified revenue levels achieving product development targets or obtaining regulatory approvals in accordance with us gaap we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date we remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations we recorded a net expense related to the change in fair value of our contingent consideration liabilities of 123 million during 2015 a net benefit related to the change in fair value of our contingent consideration liabilities of 85 million during 2014 and a net expense related to the change in fair value of our contingent consideration liabilities of 4 million during 2013 we made contingent consideration payments of 213 million 137 million and 165 million in 2015 2014 and 2013 respectively 76changes in our contingent consideration liability were as follows in millionsbalance as of december 31 2013501amounts recorded related to new acquisitions3other amounts recorded related to prior acquisitions8fair value adjustment85contingent payments related to prior period acquisition137balance as of december 31 2014274amounts recorded related to new acquisitions63other amounts recorded related to prior acquisitions1fair value adjustment123contingent payments related to prior period acquisition213balance as of december 31 2015246as of december 31 2015 the maximum amount of future contingent consideration undiscounted that we could be required to make associated with our acquisitions is approximately 1918 billion increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving regulatory revenue or commercializationbased milestones the recurring level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputscontingent consideration liabilityfair value as of december 31 2015valuation techniqueunobservable inputrangerampd and commercializationbased milestone19 milliondiscounted cash flowdiscount rate2  35probability of payment32  95projected year of payment2017  2021revenuebased payments125 milliondiscounted cash flowdiscount rate11  15projected year of payment2016  2022102 millionmonte carlorevenue volatility15risk free ratelibor term structureprojected year of payment2016  2018contingent consideration liabilities are remeasured to fair value each reporting period using projected revenues discount rates probabilities of payment and projected payment dates projected contingent payment amounts related to rampd regulatory and commercializationbased milestones and certain revenuebased milestones are discounted back to the current period using a discounted cash flow model other revenuebased payments are valued using a monte carlo valuation model which simulates future revenues during the earn outperiod using managements best estimates projected revenues are based on our most recent internal operational budgets and longrange strategic plans increases in projected revenues and probabilities of payment may result in higher fair value measurements increases in discount rates and the time to payment may result in lower fair value measurements increases or decreases in any of those inputs together or in isolation may result in a significantly lower or higher fair value measurement strategic investmentson april 30 2015 we acquired a 27 percent ownership interest in preventice inc preventice which includes 185 percent of preventices common stock preventice is a privatelyheld company headquartered in minneapolis mn and a leading developer of mobile health solutions and services preventice offers a full portfolio of wearable cardiac monitors including holter monitors cardiac event monitors and mobile cardiac telemetry in addition to the equity agreement we entered into a commercial agreement with preventice under which we have become preventices exclusive worldwide sales and marketing representative we believe this partnership strengthens our portfolio of cardiac monitoring and broader disease management capabilities 77on april 13 2015 we acquired 25 percent of the common stock of frankenman medical equipment company frankenman frankenman is a private company headquartered in suzhou china and is a local market leader in surgical staplers additionally we entered into copromotional and coselling agreements with frankenman to jointly commercialize selected products in china we believe this alliance will enable us to reach more clinicians and treat more patients in china by providing access to training on less invasive endoscopic technologies with clinical and economic benefitswe are accounting for our investments in preventice and frankenman as well as certain of our other strategic investments as equity method investments in accordance with fasb asc topic 323 investments  equity method and joint ventures the book value of investments that we accounted for under the equity method of accounting was 173 million as of december 31 2015 and 10 million as of december 31 2014 the aggregate carrying amount of our cost method investments was 45 million as of december 31 2015 and 27 million as of december 31 2014 in addition we had notes receivable from certain companies that we account for under the cost method of 30 million as of december 31 2015 and 17 million as of december 31 2014 as of december 31 2015 the book value of our equity method investments exceeded our share of the book value of the investees underlying net assets by approximately 80 million which represents amortizable intangible assets and inprocess research and development corresponding deferred tax liabilities and goodwill during the year ended december 31 2015 the net losses from our equity method adjustments presented within the other net caption of our condensed consolidated statement of operations were immaterial we did not close any material strategic investments in the twelve months ended december 31 2014note c  divestituresin january 2011 we closed the sale of our neurovascular business to stryker corporation for a purchase price of 1500 billion in cash we received 1450 billion during 2011 an additional 10 million during 2012 30 million during 2013 and we received the final amount due to us in 2014 at the time of divestiture due to our continuing involvement in the operations of the neurovascular business following the transaction the divestiture did not meet the criteria for presentation as a discontinued operation our sales related to our divested neurovascular business have declined as the various transition services and supply agreements have terminatedwe recorded a gain of 12 million during 2014 and a gain of 38 million during 2013 associated with the transaction we recorded revenue related to the neurovascular business following its divestiture of 4 million in 2014 and 58 million in 2013 note d  goodwill and other intangible assetsthe gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated writeoffs of goodwill as of december 31 2015 and 2014 is as follows   as of december 31 2015 as of december 31 2014  gross carrying accumulatedamortization gross carrying accumulatedamortizationin millions amount writeoffs amount writeoffsamortizable intangible assets        technologyrelated 8948 4054 8406 3697patents 520 358 519 342other intangible assets 1529 610 875 533  10997 5022 9800 4572unamortizable intangible assets        goodwill 16373 9900 15798 9900inprocess research and development iprampd 99   181  technologyrelated 120  197   16592 9900 16176 9900during 2015 we reclassified approximately 77 million of core technology not previously subject to amortization to amortizable intangible assets due to projected changes in the market for this technology we tested the intangible asset for impairment prior to this reclassification and determined that the asset was not impaired  78in addition during 2015 we reclassified a total of 77 million of iprampd assets not previously subject to amortization to amortizable intangible assets the reclassification of iprampd to amortizable intangible assets was primarily related to the receipt of fda approval of the watchman deviceour technologyrelated intangible assets that are not subject to amortization represent technical processes intellectual property andor institutional understanding acquired through business combinations that are fundamental to the ongoing operations of our business and have no limit to their useful life our technologyrelated intangible assets that are not subject to amortization are comprised primarily of certain acquired balloon and other technology which is foundational to our continuing operations within the cardiovascular market and other markets within interventional medicine we assess our indefinitelived intangible assets at least annually for impairment and reassess their classification as indefinitelived assets we assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinitelived intangible assets are impaired if we conclude that it is more likely than not that the asset is impaired we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with asc topic 350 intangiblesgoodwill and otherthe following represents our goodwill balance by global reportable segmentin millions cardiovascular rhythm management medsurg totalbalance as of december 31 2013 3252 294 2147 5693purchase price adjustments 2 4 2 8goodwill acquired 169  44 213other changes in carrying amount 7  7 balance as of december 31 2014 3426 290 2182 5898purchase price adjustments 2 2 2 2goodwill acquired 23  550 573balance as of december 31 2015 3451 292 2730 6473in 2014 we reallocated 7 million of goodwill between cardiovascular and medsurg as a result of the realignment of certain product lines from endoscopy to peripheral interventions as of january 1 2014the 2015 and 2014 purchase price adjustments relate primarily to adjustments in taxes payable and deferred income taxes including changes in the liability for unrecognized tax benefits2015 goodwill impairment testingwe test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may existin the second quarter of 2015 we performed our annual goodwill impairment test for all of our reporting units in accordance with asc topic 350 intangiblesgoodwill and other in conjunction with our annual test the fair value of each reporting unit exceeded its carrying value therefore it was deemed not necessary to proceed to the second step of the impairment test as a result of the 2015 annual goodwill impairment test we identified our global electrophysiology reporting unit as being at higher risk of potential failure of the first step of the goodwill impairment test in future reporting periods as of the date of our annual goodwill impairment test our global electrophysiology reporting unit had excess fair value over carrying value of approximately 28 percent and held 292 million of allocated goodwill also as of the date of our annual goodwill impairment test our global cardiac rhythm management crm reporting unit had excess fair value over carrying value of approximately 26 percent however due to goodwill impairment charges in prior years no goodwill remains within our crm reporting uniton a quarterly basis we monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill the key variables that drive the cash flows of our reporting units are estimated revenue growth rates and levels of profitability terminal value growth rate assumptions as well as the wacc are additional key variables for reporting unit cash flows these assumptions are subject to uncertainty including our ability to grow revenue and improve profitability levels relatively small declines in the future performance and cash flows of a reporting unit or asset group or small changes in other key assumptions may result in the recognition of significant goodwill impairment charges for example as of the date of our annual goodwill impairment test keeping all other variables constant a combined increase of 50 basis points in the wacc along with a simultaneous decrease of 150 basis points in the long term growth rate applied would require that we perform the second step of the goodwill impairment test for our global electrophysiology reporting unit the estimates used for  79our future cash flows and discount rates represent managements best estimates which we believe to be reasonable but future declines in business performance may result in impairment of our goodwill future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units include but are not limited todecreases in estimated market sizes or market growth rates due to greaterthanexpected declines in procedural volumes pricing pressures reductions in reimbursement levels product actions andor competitive technology developmentsdeclines in our market share and penetration assumptions due to increased competition an inability to develop or launch new and nextgeneration products and technology features in line with our commercialization strategies product actions and market andor regulatory conditions that may cause significant launch delays or product recallsdecreases in our forecasted profitability due to an inability to successfully implement and achieve timely and sustainable cost improvement measures consistent with our expectationsnegative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain productsthe level of success of ongoing and future research and development efforts including those related to recent acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new productsthe level of success in managing the growth of acquired companies achieving sustained profitability consistent with our expectations establishing government and thirdparty payer reimbursement supplying the market and increases in the costs and time necessary to integrate acquired businesses into our operations successfullychanges in our reporting units or in the structure of our business as a result of future reorganizations acquisitions or divestitures of assets or businesses andincreases in our marketparticipant riskadjusted wacc increases in our marketparticipant tax rate changes in tax laws changes in foreign currency exchange rates andor other macroeconomic conditionsnegative changes in one or more of these factors among others could result in impairment charges2013 chargesfollowing our reorganization from regions to global business units and our reallocation of goodwill on a relative fair value basis as of january 1 2013 we conducted the first step of the goodwill impairment test for all global reporting units as of january 1 2013 the fair value of each global reporting unit exceeded its carrying value with the exception of the global crm reporting unit we tested the global crm intangible assets in conjunction with the second step of the goodwill test on the global crm reporting unit and recorded a noncash goodwill impairment charge of 423 million to write down the goodwill to its implied fair value as of january 1 2013 as a result of this analysis the primary driver of this impairment charge was our reorganization from geographic regions to global business units as of january 1 2013 which changed the composition of our reporting units as a result of the reorganization any goodwill allocated to the global crm reporting unit was no longer supported by the cash flows of other businesses under our former reporting unit structure the goodwill allocated to our regional reporting units was supported by the cash flows from all businesses in each international region the hypothetical tax structure of the global crm business and the global crm business discount rate applied were also contributing factors to the goodwill impairment chargethe following is a rollforward of accumulated goodwill writeoffs by global reportable segmentin millions cardiovascular rhythm management medsurg totalaccumulated writeoffs as of december 31 2013 1479 6960 1461 9900goodwill written off    accumulated writeoffs as of december 31 2014 1479 6960 1461 9900goodwill written off    accumulated writeoffs as of december 31 2015 1479 6960 1461 9900 80intangible asset impairment charges2015 chargesduring the third quarter of 2015 we performed our annual impairment test of all iprampd projects and our indefinitelived core technology assets in addition as a result of revised estimates in conjunction with our annual operating plan we performed an interim impairment test of certain definitelived core technology associated with certain of our acquisitions based on the results of our testing we recorded impairment charges of 10 million in the third quarter of 2015during the second quarter of 2015 in conjunction with our annual strategic planning process and annual goodwill impairment test we performed an interim impairment test on certain of our iprampd projects and core technology assets based on our impairment assessment we recorded an impairment charge of 9 million in the second quarter of 20152014 chargesduring the fourth quarter of 2014 as a result of revised estimates in conjunction with our annual operating plan we performed an interim impairment test of inprocess research and development projects associated with certain of our acquisitions based on our impairment assessment and lower expected future cash flows associated with our intangible assets we recorded an impairment charge of 18 million to writedown the balances of these inprocess projects to their fair value which was determined to be zeroduring the third quarter of 2014 we performed our annual impairment test of all inprocess research and development projects and our indefinite lived core technology assets based on the results of our annual test we recorded total impairment charges of 4 million to writedown the balances of certain inprocess projects to their fair value in addition as a result of revised estimates in conjunction with our annual operating plan we performed an interim impairment test of core technology associated with certain of our acquisitions and recorded an impairment charge of 8 million for a total of 12 million of impairment charges in the third quarter of 2014 during the second quarter of 2014 as a result of revised estimates developed in conjunction with our annual strategic planning process and annual goodwill impairment test we performed an interim impairment test of our inprocess research and development projects and core technology assets associated with certain of our acquisitions based on our impairment assessment and lower expected future cash flows associated with our intangible assets we recorded impairment charges of 110 million the impairment charges were due to changes in our clinical strategy and lower estimates of the european and global hypertension markets and the resulting amount of future revenue and cash flows associated with our hypertension technology as a result we recorded impairment charges of 67 million related to these technology intangible assets in addition in the second quarter of 2014 due to revised expectations and timing as a result of the announcement of a third fda circulatory system devices panel we recorded impairment charges of 35 million related to the inprocess research and development intangible assets acquired from atritech inc atritech we also recorded an 8 million intangible asset impairment charge associated with changes in the amount of the expected cash flows related to certain other acquired inprocess research and development projects during the first quarter of 2014 as a result of lower estimates of the resistant hypertension market following the announcement of data from a competitors clinical trial we performed an interim impairment test of our hypertensionrelated inprocess research and development projects and core technology assets the impairment assessments were based upon probabilityweighted cash flows of potential future scenarios based on our impairment assessment and lower expected future cash flows associated with our hypertensionrelated intangible assets we recorded impairment charges of 55 million in the first quarter of 2014 to writedown the balance of these intangible assets to their fair value2013 chargesduring the second quarter of 2013 as a result of revised estimates developed in conjunction with our annual strategic planning process and annual goodwill impairment test we performed an interim impairment test of our inprocess research and development projects associated with certain of our acquisitions based on the results of our impairment analyses we revised our expectations of the market size related to sadra medical inc sadra and the resulting timing and amount of future revenue and cash flows associated with the technology acquired from sadra as a result of these changes we recorded impairment charges of 51 million to writedown the balance of these intangible assets to their fair value we also recorded a 2 million intangible asset impairment charge associated with changes in the amount of the expected cash flows related to certain other acquired inprocess research and development projects 81we recorded these amounts in the intangible asset impairment charges caption in our accompanying consolidated statements of operationsthe nonrecurring level 3 fair value measurements of our intangible asset impairment analysis included the following significant unobservable inputsintangible assetvaluation datefair valuevaluation techniqueunobservable inputratetechnologyrelated amortizableseptember 30 20158 millionincome approach excess earnings methoddiscount rate10inprocess rampdjune 30 20156 millionincome approach  excess earnings methoddiscount rate 165  20inprocess rampdseptember 30 201416 millionincome approach  excess earnings methoddiscount rate 165  20inprocess rampdjune 30 201483 millionincome approach  excess earnings methoddiscount rate 165  20technologyrelated amortizablejune 30 20148 millionincome approach  excess earnings methoddiscount rate15inprocess rampdmarch 31 20146 millionincome approach  excess earnings methoddiscount rate20technologyrelated amortizablemarch 31 201464 millionincome approach  excess earnings methoddiscount rate15inprocess rampdjune 30 2013178 millionincome approach  excess earnings methoddiscount rate165the intangible asset category and associated write downs recorded in 2015 2014 and 2013 were as follows  year ended december 31in millions 2015 2014 2013technologyrelated amortizable 9 107 inprocess research and development 10 88 53  19 195 53estimated amortization expense for each of the five succeeding fiscal years based upon our intangible asset portfolio as of december 31 2015 is as follows 82     estimated amortization expensefiscal year in millions 2016 5362017 5202018 5172019 5132020 510note e  fair value measurementsderivative instruments and hedging activitieswe address market risk from changes in foreign currency exchange rates and interest rates through a risk management program that includes the use of derivative financial instruments and we operate the program pursuant to documented corporate risk management policies our derivative instruments do not subject our earnings or cash flows to material risk as gains and losses on these derivatives generally offset losses and gains on the item being hedged we do not enter into derivative transactions for speculative purposes and we do not have any nonderivative instruments that are designated as hedging instruments pursuant to fasb asc topic 815 derivatives and hedging topic 815currency hedgingwe are exposed to currency risk consisting primarily of foreign currency denominated monetary assets and liabilities forecasted foreign currency denominated intercompany and thirdparty transactions and net investments in certain subsidiaries we manage our exposure to changes in foreign currency exchange rates on a consolidated basis to take advantage of offsetting transactions we use derivative instruments and nonderivative transactions to reduce the risk that our earnings and cash flows associated with these foreign currency denominated balances and transactions will be adversely affected by foreign currency exchange rate changescurrently or previously designated foreign currency hedgesall of our designated currency hedge contracts outstanding as of december 31 2015 and december 31 2014 were cash flow hedges under topic 815 intended to protect the us dollar value of our forecasted foreign currency denominated transactions we record the effective portion of any change in the fair value of foreign currency cash flow hedges in other comprehensive income until the related thirdparty transaction occurs once the related thirdparty transaction occurs we reclassify the effective portion of any related gain or loss on the foreign currency cash flow hedge to earnings in the event the hedged forecasted transaction does not occur or it becomes no longer probable that it will occur we reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time we had currency derivative instruments designated as cash flow hedges outstanding in the contract amount of 1458 billion as of december 31 2015 and 2178 billion as of december 31 2014we recognized net gains of 213 million during 2015 on our cash flow hedges as compared to 105 million of net gains during 2014 and 36 million of net gains during 2013 all currency cash flow hedges outstanding as of december 31 2015 mature within 36 months as of december 31 2015 145 million of net gains net of tax were recorded in accumulated other comprehensive income aoci to recognize the effective portion of the fair value of any currency derivative instruments that are or previously were designated as foreign currency cash flow hedges as compared to net gains of 217 million as of december 31 2014 as of december 31 2015 103 million of net gains net of tax may be reclassified to earnings within the next twelve monthsthe success of our hedging program depends in part on forecasts of transaction activity in various currencies primarily japanese yen euro british pound sterling australian dollar and canadian dollar we may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility in addition changes in foreign currency exchange rates related to any unhedged transactions may impact our earnings and cash flows 83nondesignated foreign currency contractswe use currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities these currency forward contracts are not designated as cash flow fair value or net investment hedges under topic 815 are markedtomarket with changes in fair value recorded to earnings and are entered into for periods consistent with currency transaction exposures generally less than one year we had currency derivative instruments not designated as hedges under topic 815 outstanding in the contract amount of 2090 billion as of december 31 2015 and 2470 billion as of december 31 2014interest rate hedgingour interest rate risk relates primarily to us dollar borrowings partially offset by us dollar cash investments we have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates by converting fixedrate debt into floatingrate debt or floatingrate debt into fixedrate debtwe designate these derivative instruments either as fair value or cash flow hedges under topic 815 we record changes in the value of fair value hedges in interest expense which is generally offset by changes in the fair value of the hedged debt obligation interest payments made or received related to our interest rate derivative instruments are included in interest expense we record the effective portion of any change in the fair value of derivative instruments designated as cash flow hedges as unrealized gains or losses in oci net of tax until the hedged cash flow occurs at which point the effective portion of any gain or loss is reclassified to earnings we record the ineffective portion of our cash flow hedges in interest expense in the event the hedged cash flow does not occur or it becomes no longer probable that it will occur we reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that timein the fourth quarter of 2013 we entered into interest rate derivative contracts having a notional amount of 450 million to convert fixedrate debt into floatingrate debt which we designated as fair value hedges during the first quarter of 2015 we terminated these hedges and we received total proceeds of approximately 35 million which included approximately 7 million of net accrued interest receivable we assessed at inception and reassessed on an ongoing basis whether the interest rate derivative contracts were highly effective in offsetting changes in the fair value of the hedged fixed rate debt in 2015 we recognized in interest expense an 8 million loss on our hedged debt compared to a 29 million loss on our hedged debt in 2014 we also recognized in interest expense an 8 million gain on the related interest rate derivative contracts during 2015 compared to a 29 million gain on these contracts during 2014 this resulted in net gains of less than 1 million recorded in earning due to ineffectiveness in 2015 and 2014during the second quarter of 2015 we entered into forward starting interest rate derivative contracts having a notional amount of 450 million to hedge interest rate risk associated with a planned issuance of fixedrate senior notes which we designated as cash flow hedges these hedges were terminated during the second quarter at the time we issued the fixedrate senior notes and we received total proceeds of approximately 11 million we had no amounts outstanding under these hedges as of december 31 2015 we assessed at inception and reassessed on an ongoing basis whether the cash flow derivative contracts were highly effective in offsetting changes in interest rates the gain on this derivative contract was recorded within accumulated other comprehensive income and is being amortized into earnings as a reduction to interest expense over the life of the related senior noteswe are amortizing the gains and losses on previously terminated interest rate derivative instruments including fixedtofloating interest rate contracts designated as fair value hedges and forward starting interest rate derivative contracts and treasury locks designated as cash flow hedges into earnings as a component of interest expense over the remaining term of the hedged debt in accordance with topic 815 the carrying amount of certain of our senior notes included unamortized gains of 63 million as of december 31 2015 and 45 million as of december 31 2014 and unamortized losses of 1 million as of december 31 2015 and 2 million as of december 31 2014 related to the fixedtofloating interest rate contracts in addition we had pretax net gains within aoci related to terminated forward starting interest rate derivative contracts and treasury locks of 10 million as of december 31 2015 and 2 million as of december 31 2014 the net gains that we recognized in earnings related to previously terminated interest rate derivatives were 13 million in 2015 9 million in 2014 and 10 million in 2013 as of december 31 2015 13 million of net gains may be reclassified to earnings within the next twelve months from amortization of our previously terminated interest rate derivative contracts 84counterparty credit riskwe do not have significant concentrations of credit risk arising from our derivative financial instruments whether from an individual counterparty or a related group of counterparties we manage our concentration of counterparty credit risk on our derivative instruments by limiting acceptable counterparties to a diversified group of major financial institutions with investment grade credit ratings limiting the amount of credit exposure to each counterparty and by actively monitoring their credit ratings and outstanding fair values on an ongoing basis furthermore none of our derivative transactions are subject to collateral or other security arrangements and none contain provisions that are dependent on our credit ratings from any credit rating agencywe also employ master netting arrangements that reduce our counterparty payment settlement risk on any given maturity date to the net amount of any receipts or payments due between us and the counterparty financial institution thus the maximum loss due to credit risk by counterparty is limited to the unrealized gains in such contracts net of any unrealized losses should any of these counterparties fail to perform as contracted although these protections do not eliminate concentrations of credit risk as a result of the above considerations we do not consider the risk of counterparty default to be significantfair value of derivative instrumentsthe following presents the effect of our derivative instruments designated as cash flow hedges under topic 815 on our accompanying consolidated statements of operations during 2015 2014 and 2013 in millions amount of pretaxgain lossrecognized in ocieffective portion amount of pretaxgain lossreclassified fromaoci into earningseffective portion location in statement ofoperationsyear ended december 31 2015     interest rate contracts11 2 interest expensecurrency hedge contracts98 213 cost of products sold 109 215  year ended december 31 2014     interest rate contracts 1 interest expensecurrency hedge contracts227 105 cost of products sold 227 106  year ended december 31 2013     interest rate contracts 1 interest expensecurrency hedge contracts207 36 cost of products sold 207 37  the amount of gain loss recognized in earnings related to the ineffective portion of hedging relationships was de minimus in all periods presentednet gains and losses on currency hedge contracts not designated as hedging instruments were offset by net losses and gains from foreign currency transaction exposures as shown in the following tablein millions   location in statement ofoperations year ended december 31   2015 2014 2013  gain loss on currency hedge contracts 48 52 45 other netgain loss on foreign currency transaction exposures 69 70 56 other netnet foreign currency gain loss 21 18 11  topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet we determine the fair value of our derivative instruments using the framework prescribed by asc topic 820 fair value measurements and disclosures by considering the estimated amount we would receive or pay to transfer these instruments at the  85reporting date and by taking into account current interest rates foreign currency exchange rates the creditworthiness of the counterparty for assets and our creditworthiness for liabilities in certain instances we may utilize financial models to measure fair value in doing so we use inputs that include quoted prices for similar assets or liabilities in active markets quoted prices for identical or similar assets or liabilities in markets that are not active other observable inputs for the asset or liability and inputs derived principally from or corroborated by observable market data by correlation or other means as of december 31 2015 and 2014 we have classified all of our derivative assets and liabilities within level 2 of the fair value hierarchy prescribed by topic 820 as discussed below because these observable inputs are available for substantially the full term of our derivative instrumentsthe following are the balances of our derivative assets and liabilities as of december 31 2015 and december 31 2014  as of  december 31 december 31in millionslocation in balance sheet 12015 2014derivative assets    designated hedging instruments    currency hedge contractsother current assets138 178currency hedge contractsother longterm assets66 141interest rate contractsother current assets 3interest rate contractsother longterm assets 22  204 344nondesignated hedging instruments    currency hedge contractsother current assets33 100total derivative assets 237 444     derivative liabilities    designated hedging instruments    currency hedge contractsother current liabilities1 1     nondesignated hedging instruments    currency hedge contractsother current liabilities22 35total derivative liabilities 23 361we classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or lessother fair value measurementsrecurring fair value measurementson a recurring basis we measure certain financial assets and financial liabilities at fair value based upon quoted market prices where available where quoted market prices or other observable inputs are not available we apply valuation techniques to estimate fair value topic 820 establishes a threelevel valuation hierarchy for disclosure of fair value measurements the categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value the three levels of the hierarchy are defined as followslevel 1  inputs to the valuation methodology are quoted market prices for identical assets or liabilitieslevel 2  inputs to the valuation methodology are other observable inputs including quoted market prices for similar assets or liabilities and marketcorroborated inputslevel 3  inputs to the valuation methodology are unobservable inputs based on managements best estimate of inputs market participants would use in pricing the asset or liability at the measurement date including assumptions about risk 86assets and liabilities measured at fair value on a recurring basis consist of the following as of december 31 2015 and december 31 2014 as of december 31 2015 as of december 31 2014in millionslevel 1 level 2 level 3 total level 1 level 2 level 3 totalassets               money market and government funds118   118 151   151currency hedge contracts 237  237  419  419interest rate contracts     25  25 118 237  355 151 444  595liabilities               currency hedge contracts 23  23  36  36accrued contingent consideration  246 246   274 274  23 246 269  36 274 310our investments in money market and government funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices these investments are classified as cash and cash equivalents within our accompanying consolidated balance sheets in accordance with us gaap and our accounting policies in addition to 118 million invested in money market and government funds as of december 31 2015 we had 31 million in shortterm time deposits and 170 million in interest bearing and noninterest bearing bank accounts in addition to 151 million invested in money market and government funds as of december 31 2014 we had 255 million in shortterm time deposits and 181 million in interest bearing and noninterest bearing bank accounts our recurring fair value measurements using significant unobservable inputs level 3 relate solely to our contingent consideration liability refer to note b  acquisitions and strategic investments for a discussion of the changes in the fair value of our contingent consideration liabilitynonrecurring fair value measurementswe hold certain assets and liabilities that are measured at fair value on a nonrecurring basis in periods subsequent to initial recognition the fair value of a cost method investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment the aggregate carrying amount of our cost method investments was 45 million as of december 31 2015 and 27 million as of december 31 2014 during 2015 2014 and 2013 we recorded charges of 19 million 195 million and 476 million respectively to adjust our goodwill and certain other intangible asset balances to their fair value refer to note d  goodwill and other intangible assets for further information related to these charges and significant unobservable inputsthe fair value of our outstanding debt obligations was 5887 billion as of december 31 2015 and 4613 billion as of december 31 2014 which was determined by using quoted market prices for our publiclyregistered senior notes classified as level 1 within the fair value hierarchy refer to note f  borrowings and credit arrangements for a discussion of our debt obligationsnote f  borrowings and credit arrangementswe had total debt of 5677 billion as of december 31 2015 and 4244 billion as of december 31 2014 the debt maturity schedule for the significant components of our debt obligations as of december 31 2015 is as followsin millions2016 2017 2018 2019 2020 thereafter totalsenior notes 250 600  1450 2350 4650term loans 85 390 150 375  1000  335 990 150 1825 2350 5650 note the table above does not include unamortized discounts associated with our senior notes or amounts related to interest rate contracts used to hedge the fair value of certain of our senior notes or debt issuance costs 87revolving credit facilityon april 10 2015 we entered into a new 2000 billion revolving credit facility the 2015 facility with a global syndicate of commercial banks and terminated our previous 2000 billion revolving credit facility the 2015 facility matures on april 10 2020 eurodollar and multicurrency loans under the 2015 facility bear interest at libor plus an interest margin of between 0900 percent and 1500 percent based on our corporate credit ratings and consolidated leverage ratio 1300 percent as of december 31 2015 in addition we are required to pay a facility fee based on our credit ratings consolidated leverage ratio and the total amount of revolving credit commitments regardless of usage under the agreement 0200 percent as of december 31 2015 the 2015 facility contains covenants which among other things require that we maintain a minimum interest coverage ratio of 30 times consolidated ebitda and a maximum leverage ratio of 45 times consolidated ebitda for the first four fiscal quarterends following the closing of the ams portfolio acquisition on august 3 2015 and decreasing to 425 times 400 times and 375 times consolidated ebitda for the next three fiscal quarterends after such four fiscal quarterends respectively and then to 350 times for each fiscal quarterend thereafter there were no amounts borrowed under our current and prior revolving credit facilities as of december 31 2015 or december 31 2014 our revolving credit facility agreement in place as of december 31 2015 requires that we maintain certain financial covenants as follows covenantrequirement actual as of december 31 2015maximum leverage ratio 145 times 30 timesminimum interest coverage ratio 230 times 66 times1ratio of total debt to consolidated ebitda as defined by the credit agreement for the preceding four consecutive fiscal quarters 2ratio of consolidated ebitda as defined by the credit agreement to interest expense for the preceding four consecutive fiscal quartersthe credit agreement for the 2015 facility provides for an exclusion from the calculation of consolidated ebitda as defined by the agreement through the credit agreement maturity of any noncash charges and up to 620 million in restructuring charges and restructuringrelated expenses related to our current or future restructuring plans as of december 31 2015 we had 558 million of the restructuring charge exclusion remaining in addition any cash litigation payments net of any cash litigation receipts as defined by the agreement are excluded from the calculation of consolidated ebitda and any new debt issued to fund any tax deficiency payments is excluded from consolidated total debt as defined in the agreement provided that the sum of any excluded net cash litigation payments and any new debt issued to fund any tax deficiency payments not exceed 2000 billion in the aggregate as of december 31 2015 we had approximately 1803 billion of the combined legal and debt exclusion remaining on october 23 2015 the definition of consolidated ebita was amended to exclude 300 million of litigation payments paid after the closing date of the 2015 facility pursuant to the february 13 2015 settlement agreement with johnson amp johnson and the other parties thereto as of and through december 31 2015 we were in compliance with the required covenantsany inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants both of which could result in additional borrowing costs further there can be no assurance that our lenders would agree to such new terms or grant such waiversterm loansas of december 31 2015 we had an aggregate 1000 billion outstanding under our unsecured term loan facilities and 400 million outstanding under these facilites as of december 31 2014 these facilities include an unsecured term loan facility entered into in august 2013 2013 term loan which had 250 million outstanding as of december 31 2015 and 400 million outstanding as of december 31 2014 along with an unsecured term loan credit facility entered into in april 2015 2015 term loan which had 750 million outstanding as of december 31 2015borrowings under the 2013 term loan bear interest at libor plus an interest margin of between 10 percent and 175 percent currently 15 percent based on our corporate credit ratings and consolidated leverage ratio we repaid 150 million of our 2013 term loan facility during 2015 as a result and in accordance with the credit agreement the remaining amount outstanding is payable with 10 million due in the fourth quarter of 2017 20 million due in both the first and second quarters of 2018 and the remaining principal amount due at the final maturity date in august 2018 the 2013 term loan borrowings are repayable at any time without premium or penalty our term loan facility requires that we comply with certain covenants including financial covenants with respect to maximum leverage and minimum interest coverage consistent with the 2015 facility the maximum  88leverage ratio requirement is 45 times our actual leverage ratio as of december 31 2015 is 30 times and the minimum interest coverage ratio requirement is 30 times our actual interest coverage ratio as of december 31 2015 is 66 times on april 10 2015 we entered into a new 750 million unsecured term loan credit facility 2015 term loan which matures on august 3 2020 the 2015 term loan was funded on august 3 2015 and was used to partially fund the ams portfolio acquisition including the payment of fees and expenses term loan borrowings under this facility bear interest at libor plus an interest margin of between 100 percent and 175 percent currently 150 percent based on our corporate credit ratings and consolidated leverage ratio the 2015 term loan requires quarterly principal payments of 38 million commencing in the third quarter of 2017 and the remaining principal amount is due at the final maturity date of august 3 2020 the 2015 term loan agreement requires that we comply with certain covenants including financial covenants with respect to maximum leverage and minimum interest coverage consistent with the 2015 facility the maximum leverage ratio requirement is 45 times our actual leverage ratio as of december 31 2015 is 30 times and the minimum interest coverage ratio requirement is 30 times our actual interest coverage ratio as of december 31 2015 is 66 times senior noteswe had senior notes outstanding of 4650 billion as of december 31 2015 and 3800 billion outstanding as of december 31 2014 in may 2015 we completed the offering of 1850 billion in aggregate principal amount of senior notes consisting of 600 million in aggregate principal amount of 2850 notes due 2020 500 million in aggregate principal amount of 3375 notes due 2022 and 750 million in aggregate principal amount of 3850 notes due 2025 the net proceeds from the offering of the notes after deducting underwriting discounts and estimated offering expenses were approximately 1830 billion we used a portion of the net proceeds from the senior notes offering to redeem 400 million aggregate principal amount of our 5500 notes due november 2015 and 600 million aggregate principal amount of our 6400 notes due june 2016 the remaining senior notes offering proceeds together with the 2015 term loan were used to fund the ams portfolio acquisition we recorded a charge of 45 million in interest expense for premiums accelerated amortization of debt issuance costs and investor discount costs net of interest rate hedge gains related to the early debt extinguishment our senior notes were issued in public offerings are redeemable prior to maturity and are not subject to any sinking fund requirements our senior notes are unsecured unsubordinated obligations and rank on parity with each other these notes are effectively junior to borrowings under our credit and security facility to the extent if directly borrowed by our subsidiaries and to liabilities of our subsidiaries see other arrangements below our senior notes consist of the following as of december 31 2015 amountin millions issuancedate maturity date semiannualcoupon ratejanuary 2017 notes250 november 2004 january 2017 5125october 2018 notes600 august 2013 october 2018 2650january 2020 notes850 december 2009 january 2020 6000may 2020 notes600 may 2015 may 2020 2850may 2022 notes500 may 2015 may 2022 3375may 2025 notes750 may 2015 may 2025 3850october 2023 notes450 august 2013 october 2023 4125november 2035 notes350 november 2005 november 2035 6250january 2040 notes300 december 2009 january 2040 7375 4650      our 4050 billion of senior notes issued in 2009 2013 and 2015 contain a changeincontrol provision which provides that each holder of the senior notes may require us to repurchase all or a portion of the notes at a price equal to 101 percent of the aggregate repurchased principal plus accrued and unpaid interest if a rating event as defined in the indenture occurs as a result of a changeincontrol as defined in the indenture any other credit rating changes may impact our borrowing cost but do not require us to repay any borrowings the interest rate payable on our november 2035 notes is currently 700 percent corporate credit rating improvements may result in a decrease in the adjusted interest rate on our november 2035 notes to the extent that our lowest credit rating is above bbb or baa3 the interest rates on our november 2035 notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either a or a3 or higher 89other arrangementswe also maintain a 300 million credit and security facility secured by our us trade receivables maturing on june 9 2017 the credit and security facility requires that we maintain a maximum leverage covenant consistent with the 2015 facility the maximum leverage ratio requirement is 45 times and our actual leverage ratio as of december 31 2015 is 30 times we had no borrowings outstanding under this facility as of december 31 2015 and december 31 2014we have accounts receivable factoring programs in certain european countries that we account for as sales under asc topic 860 transfers and servicing these agreements provide for the sale of accounts receivable to third parties without recourse of up to approximately 392 million as of december 31 2015 we have no retained interests in the transferred receivables other than collection and administrative responsibilities and once sold the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy we derecognized 151 million of receivables as of december 31 2015 at an average interest rate of 24 percent and 167 million as of december 31 2014 at an average interest rate of 32 percentin addition we have uncommitted credit facilities with a commercial japanese bank that provide for borrowings promissory notes discounting and receivables factoring of up to 210 billion japanese yen approximately 175 million as of december 31 2015 we derecognized 132 million of notes receivable as of december 31 2015 at an average interest rate of 16 percent and 134 million of notes receivable as of december 31 2014 at an average interest rate of 18 percent derecognized accounts and notes receivable are excluded from trade accounts receivable net in the accompanying consolidated balance sheetsas of december 31 2015 we had outstanding letters of credit of 44 million as compared to 59 million as of december 31 2014 which consisted primarily of bank guarantees and collateral for workers compensation insurance arrangements as of december 31 2015 and 2014 none of the beneficiaries had drawn upon the letters of credit or guarantees accordingly we have not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets as of december 31 2015 or 2014 we believe we will generate sufficient cash from operations to fund these payments and intend to fund these payments without drawing on the letters of creditnote g  leasesrent expense amounted to 76 million in 2015 76 million in 2014 and 77 million in 2013future minimum rental commitments as of december 31 2015 under all noncancelable lease agreements including capital leases were as follows in millions201658201744201836201927202021thereafter43   229  note h  restructuringrelated activitieson an ongoing basis we monitor the dynamics of the economy the healthcare industry and the markets in which we compete and we continue to assess opportunities for improved operational effectiveness and efficiency and better alignment of expenses with revenues while preserving our ability to make the investments in research and development projects capital our people and other programs that we believe are important to drive our growth as a result of these assessments we have undertaken various restructuring initiatives in order to enhance our growth potential and position us for longterm success these initiatives are described below2014 restructuring planon october 22 2013 our board of directors approved and we committed to a restructuring initiative the 2014 restructuring plan the 2014 restructuring plan is intended to build on the progress we have made to address financial pressures in a changing global marketplace further strengthen our operational effectiveness and efficiency and support new growth investments key activities under the plan include continued implementation of our ongoing plant network optimization pno strategy continued focus on driving operational efficiencies and ongoing business and commercial model changes the pno strategy is intended to  90simplify our manufacturing plant structure by transferring certain production lines among facilities other activities involve rationalizing organizational reporting structures to streamline various functions eliminate bureaucracy increase productivity and better align resources to business strategies and marketplace dynamics these activities were initiated in the fourth quarter of 2013 and were substantially completed by the end of 2015 except for certain activities associated with our plant network optimization strategy which we expect to substantially complete by the end of 2016we estimate that the implementation of the 2014 restructuring plan will result in total pretax charges of approximately 255 million to 270 million and approximately 240 million to 255 million of these charges are expected to result in cash outlays of which we have made payments of 189 million to date we have recorded related costs of 229 million since the inception of the plan and are recording a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operations the following table provides a summary of our estimates of costs associated with the 2014 restructuring plan by major type of costtype of costtotal estimated amount expected tobe incurredrestructuring charges termination benefits95 million to 100 millionother 130 million to 35 millionrestructuringrelated expenses other 2130 million to 135 million 255 million to 270 million1 consists primarily of consulting fees and costs associated with contractual cancellations2 comprised of other costs directly related to the 2014 restructuring plan including program management accelerated depreciation and costs to transfer product lines among facilities2011 restructuring planon july 26 2011 our board of directors approved and we committed to a restructuring initiative the 2011 restructuring plan designed to strengthen operational effectiveness and efficiencies increase competitiveness and support new investments key activities under the 2011 restructuring plan included standardizing and automating certain processes and activities relocating select administrative and functional activities rationalizing organizational reporting structures leveraging preferred vendors and other efforts to eliminate inefficiency among these efforts we expanded our ability to deliver bestinclass global shared services for certain functions and divisions at several locations in emerging markets on january 25 2013 our board of directors approved and we committed to an expansion of the 2011 restructuring plan the expansion the expansion was intended to further strengthen our operational effectiveness and efficiencies and support new investments activities under the 2011 restructuring plan were initiated in the third quarter of 2011 and all activities including those related to the expansion were substantially completed by the end of 2013the 2011 restructuring plan including the expansion resulted in total pretax charges of approximately 286 million and 287 million of cash outlays in addition we received 53 million of cash proceeds on facility and fixed asset sales we recorded a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operations the following provides a summary of our total costs associated with the 2011 restructuring plan including the expansion by major type of costtype of costtotal amount incurredrestructuring charges termination benefits135 millionother 1112 millionrestructuringrelated expenses other 239 million 286 million1includes primarily consulting fees gains and losses on fixed asset disposals and costs associated with contractual cancellations 2comprised of other costs directly related to the 2011 restructuring plan including the expansion such as program management accelerated depreciation retention and infrastructurerelated costs  91in aggregate we recorded restructuring charges pursuant to our restructuring plans of 26 million during 2015 69 million during 2014 and 101 million during 2013 in addition we recorded expenses within other lines of our accompanying consolidated statements of operations related to our restructuring initiatives of 57 million during 2015 48 million during 2014 and 23 million during 2013the following presents these costs by major type and line item within our accompanying consolidated statements of operations as well as by programyear ended december 31 2015         in millionsterminationbenefits accelerateddepreciation transfercosts other totalrestructuring charges23   3 26restructuringrelated expenses         cost of products sold  31  31selling general and administrative expenses 3  23 26  3 31 23 57 23 3 31 26 83          in millionsterminationbenefits accelerateddepreciation transfercosts other total2014 restructuring plan27 3 31 26 872011 restructuring plan4    4 23 3 31 26 83          year ended december 31 2014         in millionsterminationbenefits accelerateddepreciation transfercosts other totalrestructuring charges42   27 69restructuringrelated expenses         cost of products sold  24  24selling general and administrative expenses 5  19 24  5 24 19 48 42 5 24 46 117          in millionsterminationbenefits accelerateddepreciation transfercosts other total2014 restructuring plan41 5 24 43 1132011 restructuring plan1   3 4 42 5 24 46 117           92year ended december 31 2013         in millionsterminationbenefits accelerateddepreciation net gain on fixed asset disposal other totalrestructuring charges60  15 56 101restructuringrelated expenses         selling general and administrative expenses 3  20 23  3  20 23 60 3 15 76 124          in millionsterminationbenefits accelerateddepreciation net gain on fixed asset disposal other total2014 restructuring plan29   1 302011 restructuring plan37 3 15 75 100substantially completed restructuring programs6    6 60 3 15 76 124          in 2013 we recorded a 6 million credit for the release of certain termination benefit accruals related to restructuring programs that were substantially complete by the end of 2012termination benefits represent amounts incurred pursuant to our ongoing benefit arrangements and amounts for onetime involuntary termination benefits and have been recorded in accordance with asc topic 712 compensation  nonretirement postemployment benefits and asc topic 420 exit or disposal cost obligations topic 420 we expect to record additional termination benefits related to our restructuring initiatives in 2016 as we complete our 2014 restructuring plan other restructuring costs which represent primarily consulting fees are being recorded as incurred in accordance with topic 420 accelerated depreciation is being recorded over the adjusted remaining useful life of the related assets and production line transfer costs are being recorded as incurredwe have incurred cumulative restructuring charges related to our 2014 restructuring plan and 2011 restructuring plan including the expansion of 372 million and restructuringrelated costs of 143 million since we committed to each plan the following presents these costs by major type and by planin millions2014 restructuringplan 2011restructuringplan including the expansion totaltermination benefits96 135 231fixed asset writeoffs 1 1other29 113 142total restructuring charges125 247 372accelerated depreciation8 5 13transfer costs55  55other41 34 75restructuringrelated expenses104 39 143 229 286 515 93we made cash payments of 95 million in 2015 associated with restructuring initiatives pursuant to these plans and have made total cash payments of 476 million related to our 2014 restructuring plan and 2011 restructuring plan including the expansion since committing to each plan each of these payments was made using cash generated from operations and are comprised of the followingin millions2014 restructuringplan 2011restructuringplan including the expansion totalyear ended december 31 2015     termination benefits37  37transfer costs31  31other27  27 95  95      program to date     termination benefits69 133 202transfer costs55  55other65 154 219 189 287 476our restructuring liability is primarily comprised of accruals for termination benefits the following is a rollforward of the termination benefit liability associated with our 2014 restructuring plan and 2011 restructuring plan including the expansion since the inception of the respective plan which is reported as a component of accrued expenses included in our accompanying consolidated balance sheets restructuring plan termination benefits      in millions2014 2011 totalaccrued as of december 31 2012 36 36charges29 37 66cash payments 61 61accrued as of december 31 201329 12 41charges41 1 42cash payments31 9 40accrued as of december 31 201439 4 43charges27 4 23cash payments37  37accrued as of december 31 201529  29in addition to our accrual for termination benefits we had a 3 million liability as of december 31 2015 and a 6 million liability as of december 31 2014 for other restructuringrelated items 94note i  supplemental balance sheet informationcomponents of selected captions in our accompanying consolidated balance sheets are as followstrade accounts receivable net  as ofin millions december 31 2015december 31 2014accounts receivable 13941288less allowance for doubtful accounts 7576less allowance for sales returns 4429  12751183the following is a rollforward of our allowance for doubtful accounts for 2015 2014 and 2013  year ended december 31in millions 201520142013beginning balance 768188net charges to expenses 15105utilization of allowances 161512ending balance 757681inventories  as ofin millions december 31 2015december 31 2014finished goods 706649workinprocess 10297raw materials 208200  1016946property plant and equipment net  as ofin millions december 31 2015december 31 2014land 8680buildings and improvements 981944equipment furniture and fixtures 27932633capital in progress 202189  40623846less accumulated depreciation 25722339  14901507accrued expenses  as ofin millions december 31 2015december 31 2014legal reserves 773694payroll and related liabilities 504512accrued contingent consideration 119158other 574586  19701950 95other longterm liabilities  as ofin millions december 31 2015december 31 2014accrued income taxes 12531231legal reserves 1163883accrued contingent consideration 127116other longterm liabilities 431436  29742666note j  income taxesour income loss before income taxes consisted of the following  year ended december 31in millions 201520142013domestic 16231263774foreign 973754551  650509223the related benefit for income taxes consisted of the following  year ended december 31in millions 201520142013current     federal 59246 state 359 foreign 132111105  194104142     deferred     federal 545458212 state 412317 foreign 191315  605494244  411390102 96the reconciliation of income taxes at the federal statutory rate to the actual benefit for income taxes is as follows  year ended december 31  201520142013us federal statutory income tax rate 350350350state income taxes net of federal benefit 486579effect of foreign taxes 344291634acquisitionrelated 60 7535 research credit 4470122valuation allowance 23 40 120goodwill impairment charges   652 compensationrelated 16 07 17 nondeductible expenses 24 19 90 uncertain domestic tax positions 27 20 70 other net 04 0219  632767460     we had net deferred tax liabilities of 264 million as of december 31 2015 and 799 million as of december 31 2014 gross deferred tax liabilities of 1875 billion as of december 31 2015 and 2096 billion as of december 31 2014 relate primarily to intangible assets acquired in connection with our prior acquisitions gross deferred tax assets of 1611 billion as of december 31 2015 and 1297 billion as of december 31 2014 relate primarily to the establishment of inventory and productrelated reserves litigation product liability and other reserves and accruals compensation related accruals net operating loss carryforwards and tax credit carryforwards and the federal benefit of uncertain tax positionswe reduce our deferred tax assets by a valuation allowance if based upon the weight of available evidence it is more likely than not that we will not realize some portion or all of the deferred tax assets we consider relevant evidence both positive and negative to determine the need for a valuation allowance information evaluated includes our financial position and results of operations for the current and preceding years the availability of deferred tax liabilities and tax carrybacks as well as an evaluation of currently available information about future years  97significant components of our deferred tax assets and liabilities are as follows  as of december 31 in millions 2015 2014      deferred tax assets    inventory costs and related reserves 49 46tax benefit of net operating loss and credits 742 525reserves and accruals 232 232restructuringrelated charges 17 20litigation and product liability reserves 689 556investment writedown 7 4compensation related 138 150federal benefit of uncertain tax positions 197 178other 39 36  2110 1747less valuation allowance 499 450  1611 1297 deferred tax liabilities    property plant and equipment 44 67unrealized gains and losses on derivative financial instruments 82 146intangible assets 1749 1883  1875 2096      net deferred tax liabilities 264 799     prepaid on intercompany profit 63 69 total net deferred tax liabilities and prepaid on intercompany profit 201 730our deferred tax assets deferred tax liabilities and prepaid on intercompany profit are included in the following locations within our accompanying consolidated balance sheets in millions location inas of december 31componentbalance sheet20152014current deferred tax asset and prepaid on intercompany profitdeferred income taxes496447noncurrent deferred tax assetother longterm assets4039deferred tax assets and prepaid on intercompany profit 536486    current deferred tax liabilityother current liabilities22noncurrent deferred tax liabilitydeferred income taxes7351214deferred tax liabilities 7371216    net deferred tax liabilities and prepaid on intercompany profit 201730as of december 31 2015 we had us tax net operating loss carryforwards and tax credits the tax effect of which was 624 million as compared to 335 million as of december 31 2014 in addition we had foreign tax net operating loss carryforwards and tax credits the tax effect of which was 288 million as of december 31 2015 as compared to 304 million as of december 31 2014 these tax attributes will expire periodically beginning in 2016 the current accounting standard for stockbased compensation prohibits the recognition of windfall tax benefits from stockbased compensation deducted for tax return purposes until realized through a reduction of income taxes payable we have 32 million  98and 2 million of us tax net operating loss as of december 31 2015 and december 31 2014 respectively which will be recognized through additional paid in capital upon realization of the tax benefit through reduction of income tax payable these amounts were not included in the gross deferred taxes as of december 31 2015 and december 31 2014after consideration of all positive and negative evidence we believe that it is more likely than not that a portion of the deferred tax assets will not be realized as a result we established a valuation allowance of 499 million as of december 31 2015 and 450 million as of december 31 2014 representing an increase of 49 million the increase in the valuation allowance as of december 31 2015 as compared to december 31 2014 is attributable primarily to increases in certain deferred tax assets that are not more likely than not realizable the income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders equity was a charge of 25 million in 2015 a charge of 21 million in 2014 and a charge of 76 million in 2013 we have not provided us income taxes and foreign withholding taxes on the undistributed earnings of foreign subsidiaries as of december 31 2015 because we intend to permanently reinvest such earnings outside the us as of december 31 2015 the cumulative amount of excess financial reporting basis over the tax basis of investments in foreign subsidiaries that is indefinitely reinvested is approximately 89 billion generally such amounts become subject to us taxation upon the remittance of dividends and under certain other circumstances it is not practicable to estimate the amount of deferred tax liability related to investments in these foreign subsidiarieswe obtain tax incentives through free trade zone regime offered in costa rica which allows 100 exemption from income tax in the first eight years of operations and 50 exemption in the following four years this tax incentive resulted in income tax savings of 7 million for 2015 7 million for 2014 and 6 million for 2013 the tax incentive for 100 exemption from income tax is expected to expire in 2023 the impact of per share earnings is immaterial for 2015 2014 and 2013as of december 31 2015 we had 1056 billion of gross unrecognized tax benefits of which a net 900 million if recognized would affect our effective tax rate as of december 31 2014 we had 1047 billion of gross unrecognized tax benefits of which a net 903 million if recognized would affect our effective tax rate as of december 31 2013 we had 1102 billion of gross unrecognized tax benefits of which a net 941 million if recognized would affect our effective tax rate a reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows in millions  year ended december 31  2015 2014 2013       beginning balance 1047 1102 1088additions based on positions related to the current year 32 44 59additions based on positions related to prior years 38 3 43reductions for tax positions of prior years 36 87 42settlements with taxing authorities 18 5 15statute of limitation expirations 7 10 31ending balance 1056 1047 1102we are subject to us federal income tax as well as income tax of multiple state and foreign jurisdictions we have concluded all us federal income tax matters through 2000 all foreign income tax matters through 2002 and substantially all material state and local income tax matters through 2005we have received notices of deficiency from the internal revenue service irs reflecting proposed audit adjustments for guidant corporation for its 2001 through 2006 tax years and boston scientific corporation for its 2006 and 2007 tax years the total incremental tax liability asserted by the irs for the applicable periods is 1162 billion plus interest the primary issue in dispute for all years is the transfer pricing associated with the technology license agreements between domestic and foreign subsidiaries of guidant in addition the irs has proposed adjustments in connection with the financial terms of our transaction agreement with abbott laboratories pertaining to the sale of guidants vascular intervention business to abbott in april 2006 in addition to the notices of deficiency during 2014 we received a revenue agent report from the irs reflecting significant proposed audit adjustments to our 2008 2009 and 2010 tax years based upon the same transfer pricing methodologies that the irs applied to our 2001 through 2007 tax yearswe do not agree with the transfer pricing methodologies applied by the irs or its resulting assessment in addition we believe that the irs positions with regard to these matters are inconsistent with the applicable tax laws and the existing treasury regulations  99we believe we have meritorious defenses for our tax filings and we have filed petitions with the us tax court contesting the notices of deficiency for the 2001  2007 tax years in challenge we currently expect the trial in this matter to begin in the second half of 2016 furthermore we have submitted a letter to the irs protesting the revenue agent report for the 2008  2010 tax years and requesting an administrative appeal hearing we do not believe that the irs will hear our appeal until the tax court case is concludedno payments on the net assessments would be required until the dispute is definitively resolved which based on experiences of other companies could take several years we believe our income tax reserves associated with these matters are adequate as of december 31 2015 however final resolution is uncertain and could have a material impact on our financial condition results of operations or cash flows we recognize interest and penalties related to income taxes as a component of income tax expense we had 500 million accrued for gross interest and penalties as of december 31 2015 and 443 million as of december 31 2014 the increase in gross interest and penalties was the result of 57 million recognized in our consolidated statements of operations we recognized 37 million of interest and penalties related to income taxes in 2015 recognized 26 million in 2014 and recognized 22 million in 2013it is reasonably possible that within the next 12 months we will resolve multiple issues including transfer pricing and transactional related issues with foreign federal and state taxing authorities in which case we could record a reduction in our balance of unrecognized tax benefits of up to 13 millionnote k  commitments and contingenciesthe medical device market in which we primarily participate is largely technology driven as a result intellectual property rights particularly patents and trade secrets play a significant role in product development and differentiation over the years there has been litigation initiated against us by others including our competitors claiming that our current or former product offerings infringe patents owned or licensed by them intellectual property litigation is inherently complex and unpredictable in addition competing parties frequently file multiple suits to leverage patent portfolios across product lines technologies and geographies and to balance risk and exposure between the parties in some cases several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices these forces frequently drive settlement not only for individual cases but also for a series of pending and potentially related and unrelated cases although monetary and injunctive relief is typically sought remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal accordingly the outcomes of individual cases are difficult to time predict or quantify and are often dependent upon the outcomes of other cases in other geographies during recent years we successfully negotiated closure of several longstanding legal matters and have received favorable rulings in several other matters however there continues to be outstanding intellectual property litigation adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins financial position results of operations andor liquidityin the normal course of business product liability securities and commercial claims are asserted against us similar claims may be asserted against us in the future related to events not known to management at the present time we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims the absence of significant thirdparty insurance coverage increases our potential exposure to unanticipated claims or adverse decisions product liability claims securities and commercial litigation and other legal proceedings in the future regardless of their outcome could have a material adverse effect on our financial position results of operations andor liquidityin addition like other companies in the medical device industry we are subject to extensive regulation by national state and local government agencies in the united states and other countries in which we operate from time to time we are the subject of qui tam actions and governmental investigations often involving regulatory marketing and other business practices these qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings substantial fines penalties and administrative remedies and have a material adverse effect on our financial position results of operations andor liquidityin accordance with asc topic 450 contingencies we accrue anticipated costs of settlement damages losses for product liability claims and under certain conditions costs of defense based on historical experience or to the extent specific losses are probable and estimable otherwise we expense these costs as incurred if the estimate of a probable loss is a range and no amount within the range is more likely we accrue the minimum amount of the range 100our accrual for legal matters that are probable and estimable was 1936 billion as of december 31 2015 and 1577 billion as of december 31 2014 and includes certain estimated costs of settlement damages and defense the increase in our legal accrual was primarily due to litigationrelated charges recorded during the year during 2015 2014 and 2013 we recorded litigationrelated net charges in the amount of 1105 billion 1036 billion and 221 million respectively the net charges recorded in 2015 include amounts related to transvaginal surgical mesh product liability cases and claims the mirowski lawsuit and certain other items the net charges recorded in 2014 include a 600 million charge related to the agreement between our subsidiary guidant corporation guidant and johnson amp johnson signed on february 13 2015 to settle the breach of merger agreement lawsuit brought by johnson amp johnson stemming from our acquisition of guidant in exchange we made aggregate payments totaling 600 million to johnson amp johnson during 2015 the 2014 net charges also include amounts related to transvaginal surgical mesh product liability cases and claims and certain other items we continue to assess certain litigation and claims to determine the amounts if any that management believes will be paid as a result of such claims and litigation and therefore additional losses may be accrued and paid in the future which could materially adversely impact our operating results cash flows andor our ability to comply with our debt covenantsin managements opinion we are not currently involved in any legal proceedings other than those specifically identified below which individually or in the aggregate could have a material adverse effect on our financial condition operations andor cash flows unless included in our legal accrual or otherwise indicated below a range of loss associated with any individual material legal proceeding cannot be estimated patent litigation on may 19 2005 g david jang md filed suit against us alleging breach of contract relating to certain patent rights covering stent technology the suit was filed in the us district court for the central district of california seeking monetary damages and rescission of contract after a markman ruling relating to the jang patent rights dr jang stipulated to the dismissal of certain claims alleged in the complaint with a right to appeal and the parties subsequently agreed to settle the other claims in may 2007 dr jang filed an appeal with respect to the remaining patent claims and in july 2008 the court of appeals vacated the district courts consent judgment and remanded the case back to the district court for further clarification in august 2011 the district court entered a stipulated judgment that we did not infringe the jang patent dr jang filed an appeal on september 21 2011 and on august 22 2012 the court of appeals vacated the district courts judgment and remanded the case to the district court for further proceedings on july 8 2015 a jury found that our express stent family did not literally infringe a jang patent but that the stents infringed under the doctrine of equivalents the court reserved judgment until the conclusion of further proceedings related to the doctrine of equivalents finding on september 29 2015 the court ruled that our express stent family did not infringe under the doctrine of equivalents and on october 30 2015 the court entered judgment in our favor on november 25 2015 dr jang filed a motion for judgment as a matter of law on literal infringement andor for a new trial and on november 30 2015 dr jang filed a notice of appeal on february 3 2016 the court denied dr jangs motion for a new trial and judgment as a matter of lawon september 27 2010 boston scientific scimed inc boston scientific ltd endovascular technologies inc and we filed suit against taewoong medical co ltd standard scitech inc endochoice inc and sewoon medical co ltd for infringement of three patents on stents for use in the gi system the pulnev and hankh patents and against cook medical inc and related entities for infringement of the same three patents and an additional patent the thompson patent the suit was filed in the us district court for the district of massachusetts seeking monetary damages and injunctive relief in december 2010 we amended our complaint to add infringement of six additional pulnev patents in january 2011 the defendants filed a counterclaim of invalidity and unenforceability in december 2011 we amended the complaint to add chekmed systems dba gi supply as a defendant on february 18 2014 atlas ip llc filed a complaint in the united states district court for the southern district of florida alleging that the sale of our latitude patient management system and implantable devices that communicate with the latitude device infringe a patent owned by atlas on july 9 2014 the district court granted our motion to transfer venue to the united states district court for the district of minnesota on january 12 2015 atlas dismissed its complaint on september 22 2015 atlas ip llc filed a complaint in federal court in ottawa ontario canada alleging that the sale of our latitude patient management system and implantable devices that communicate with the latitude device infringe certain claims of a canadian patent owned by atlas on september 22 2014 the board of trustees for the university of alabama filed a complaint in the united states district court for the northern district of alabama alleging that the sale of our cardiac resynchronization therapy devices infringe a patent owned by the university of alabama on august 21 2015 the court ordered a stay pending our requests for inter partes review of all claims related to the patent before the patent trial and appeal board of the us patent and trademark office our requests were rejected on september 24 2015 and october 19 2015 a trial has been scheduled to begin on may 22 2017 101on october 30 2015 a subsidiary of boston scientific filed suit against edwards lifesciences corporation and edwards lifesciences services gmbh in dsseldorf district court in germany for patent infringement we allege that edwards sapien 3 heart valve infringes our patent related to adaptive sealing technology on november 9 2015 edwards lifesciences llc filed an invalidity claim against one of our subsidiaries sadra medical inc in the high court of justice chancery division patents court in the united kingdom alleging that a european patent owned by sadra relating to a repositionable heart valve is invalid on january 15 2016 we filed our defense and counterclaim for a declaration that our european patent is valid and infringed by edwardson november 23 2015 edwards lifesciences pvt inc filed a patent infringement action against us and one of our subsidiaries boston scientific medizintechnik gmbh in the district court of dsseldorf germany alleging a european patent spenser owned by edwards is infringed by our lotus transcatheter heart valve system on november 23 2015 edwards lifesciences corporation filed a patent infringement action against us and boston scientific medizintechnik gmbh in the district court of dsseldorf germany alleging an european patent bourang owned by edwards is infringed by our lotus transcatheter heart valve system product liability litigation fewer than five individual lawsuits remain pending in state court jurisdictions against guidant alleging personal injuries associated with defibrillators or pacemakers involved in certain 2005 and 2006 product communications further we are aware of approximately 18 guidant product liability lawsuits pending in international jurisdictions associated with defibrillators or pacemakers including devices involved in the 2005 and 2006 product communications four of these suits are pending in canada involving certain models of guidant pacemakers three of which are stayed pending the outcome of one lead class action on may 8 2009 the justice of ontario court certified a class of persons in whom pacemakers were implanted in canada and a class of family members with derivative claims in each case these matters generally seek monetary damages from us this class action has been inactive since 2011 on march 24 2014 the ontario superior court approved a 3 million settlement of a class action involving certain models of guidant defibrillators we believe guidant has satisfied its obligations pursuant to the settlement agreement as of february 23 2016 over 35000 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us the pending cases are in various federal and state courts in the united states and include eight putative class actions there were also fewer than 20 cases in canada inclusive of four putative class actions and fewer than 15 claims in the united kingdom generally the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products the plaintiffs assert design and manufacturing claims failure to warn breach of warranty fraud violations of state consumer protection laws and loss of consortium claims over 3100 of the cases have been specially assigned to one judge in state court in massachusetts on february 7 2012 the judicial panel on multidistrict litigation mdl established mdl2326 in the us district court for the southern district of west virginia and transferred the federal court transvaginal surgical mesh cases to mdl2326 for coordinated pretrial proceedings during the fourth quarter of 2013 we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products we have responded to those requests during april 2015 we entered into an initial master settlement agreement with certain plaintiffs counsel to settle 2970 pending cases and claims including the case in the district court of dallas county tx for which there is a judgment of approximately 35 million that is currently subject to appeal for approximately 119 million subsequently we entered into several additional master settlement agreements with certain plaintiffs counsel as of february 23 2016 we have entered into master settlement agreements to resolve an aggregate of over 10000 cases and claims each master settlement agreement was entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing and provides that the settlement and the distribution of settlement funds to participating claimants are conditioned upon among other things achieving minimum required claimant participation thresholds if the participation thresholds under a master settlement agreement are not satisfied we may terminate that agreement in addition we continue to engage in discussions with various plaintiffs counsel regarding potential resolution of pending cases and claimson or about january 12 2016 teresa l stevens filed a claim against us and three other defendants asserting for herself and on behalf of a putative class of similarlysituated women that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from china the complaint was filed in the united states district court for the southern district of west virginia before the same court that is hearing the mesh mdl the complaint which alleges racketeer influenced and corrupt organizations act rico violations fraud misrepresentation deceptive trade practices and unjust enrichment seeks both equitable relief and damages under state and federal law on january 26 2016 the court issued an order staying the case and directing the plaintiff to submit information to allow the fda to issue a determination with respect to her allegations in addition we are in contact with the us attorneys office for the southern district of west virginia and are  102responding voluntarily to their requests in connection with that offices review of the allegations concerning the use of mesh resin in the complaint we deny the plaintiffs allegations and intend to defend ourselves vigorouslywe have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products while we believe that our accrual associated with this matter is adequate changes to this accrual may be required in the future as additional information becomes available while we continue to engage in discussions with plaintiffs counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us that do not settle the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations financial condition andor liquidity initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us we do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh productsgovernmental investigations and qui tam matterson august 3 2012 we were served with a qui tam complaint that had previously been filed under seal against boston scientific neuromodulation corp in the us district court for the district of new jersey on march 2 2011 on august 8 2012 we learned that the federal government had previously declined to intervene in this matter the relators complaint now unsealed alleges that boston scientific neuromodulation corp violated the federal and various states false claims acts through submission of fraudulent bills for implanted devices underreporting of certain adverse events and promotion of offlabel uses on september 10 2012 the relators filed an amended complaint revising and restating certain of the claims in the original complaint our motion to dismiss filed subsequently was denied on may 31 2013 and on june 28 2013 we answered the amended complaint and brought certain counterclaims arising from relators unauthorized removal of documents from the business during their employments which the relators moved to dismiss on july 22 2013 the court denied relators motion to dismiss the counterclaims on september 4 2014on may 5 2014 we were served with a subpoena from the us department of health and human services office of the inspector general the subpoena seeks information relating to the launch of the cognis and teligen line of devices in 2008 the performance of those devices from 2007 to 2009 and the operation of the physician guided learning program we are cooperating with this requeston february 23 2015 a judge for the court of modena italy ordered a trial for boston scientific spa and three of its employees as well as numerous other defendants charged in criminal proceedings the charges arise from allegations that the defendants made improper donations to certain health care providers and other employees of the hospital of modena in order to induce them to conduct unauthorized clinical trials as well as related government fraud in relation to the financing of such clinical trials we deny these allegations and intend to defend ourselves vigorously on december 1 2015 the brazilian governmental entity known as cade the administrative council of economic defense served a search warrant on the offices of our brazilian subsidiary as well as on the brazilian offices of several other major medical device makers who do business in brazil in furtherance of an investigation into alleged anticompetitive activity with respect to certain tender offers for government contracts we are cooperating fully with cades inquiryother proceedings on september 28 2011 we served a complaint against mirowski family ventures llc in the us district court for the southern district of indiana for a declaratory judgment that we have paid all royalties owed and did not breach any contractual or fiduciary obligations arising out of a license agreement mirowski answered and filed counterclaims requesting damages on may 13 2013 mirowski family ventures served us with a complaint alleging breach of contract in montgomery county circuit court maryland and they amended this complaint on august 1 2013 on july 29 2013 the indiana case was dismissed on september 10 2013 we removed the case to the united states district court for the district of maryland on june 5 2014 the district court granted mirowskis motion to remand the case to the montgomery county circuit court on september 24 2014 following a jury verdict against us the montgomery county circuit court entered a judgment that we breached our license agreement with mirowski and awarded damages of 308 million on october 28 2014 the montgomery county circuit court denied our posttrial motions seeking to overturn the judgment on november 19 2014 we filed an appeal with the maryland court of special appeals on january 29 2016 the maryland court of special appeals affirmed the decision of the montgomery county circuit court we plan to seek reconsideration of the decision of the maryland court of special appealson april 24 2014 dr qingsheng zhu and dr julio spinelli acting jointly on behalf of the stockholder representative committee of action medical inc action medical filed a lawsuit against us and our subsidiary cardiac pacemakers inc cpi in the us district court for the district of delaware the stockholder representatives allege that we and cpi breached a contractual  103duty to pursue development and commercialization of certain patented heart pacing methods and devices and to return certain patents a trial has been scheduled to begin on april 18 2016 refer to note j  income taxes for information regarding our tax litigation matters concluded since december 31 2014on september 25 2006 johnson amp johnson filed a lawsuit against us guidant and abbott laboratories in the us district court for the southern district of new york the complaint alleges that guidant breached certain provisions of the amended merger agreement between johnson amp johnson and guidant merger agreement as well as the implied duty of good faith and fair dealing the complaint further alleges that abbott and we tortiously interfered with the merger agreement by inducing guidants breach the complaint seeks certain factual findings damages in an amount no less than 5500 billion and attorneys fees costs and interest in august 2007 the judge dismissed the tortious interference claims against us and abbott and the implied duty of good faith and fair dealing claim against guidant on june 20 2011 guidant filed a motion for summary judgment and the hearing on this motion was held on july 25 2012 on july 7 2014 the judge denied guidants motion the bench trial was held in november and december on february 13 2015 the parties reached a settlement agreement pursuant to which guidant made aggregate payments to johnson amp johnson totaling 600 million we agreed that neither we nor our affiliates will commence or assist any third party in commencing proceedings of any kind against johnson amp johnson or its affiliates for patent infringement or seeking any remedy for patent infringement based on johnson amp johnson or its affiliates making having made using selling offering for sale or importing the smart smart control and smart flex stent products and johnson amp johnson dismissed its actions against guidant with prejudice on october 5 2007 dr tassilo bonzel filed a complaint against pfizer inc and our schneider subsidiaries and us in the district court in kassel germany alleging that a 1995 license agreement related to a catheter patent is invalid under german law and seeking monetary damages in june 2009 the district court dismissed all but one of dr bonzels claims and in october 2009 he added new claims we opposed the addition of the new claims the district court ordered dr bonzel to select the claims he would pursue and in january 2011 he made that selection a hearing was held on march 28 2014 and a decision was made to take evidence at a hearing to be set at a later date on january 23 2015 the parties reached a confidential settlement agreement on april 15 2015 all remaining boston scientific affiliates were dismissed from the case on june 27 2008 the republic of iraq filed a complaint against our whollyowned subsidiary bssa france and 92 other defendants in the us district court of the southern district of new york the complaint alleges that the defendants acted improperly in connection with the sale of products under the united nations oil for food program the complaint also alleges racketeer influenced and corrupt organizations act rico violations conspiracy to commit fraud and the making of false statements and improper payments and it seeks monetary and punitive damages on february 6 2013 the district court dismissed the complaint with prejudice on standing and jurisdictional grounds on september 18 2014 the us court of appeals for the second circuit affirmed the district courts decision to dismiss the complaint with prejudice on october 2 2014 the plaintiff filed a petition for rehearing en banc on december 2 2014 the second circuit denied the petition for rehearing en banc on march 2 2015 the plaintiff filed a petition for writ of certiorari with the united states supreme court requesting judicial review of the second circuits decision on june 15 2015 the united states supreme court denied the plaintiffs petition for writ of certiorari on september 22 2009 cordis corporation cordis llc and wyeth corporation filed a complaint for patent infringement against abbott laboratories abbott cardiovascular systems inc boston scientific scimed inc and us alleging that the promus coronary stent system supplied to us by abbott infringes a patent the llanos patent owned by cordis and wyeth the suit was filed in the us district court for the district of new jersey seeking monetary and injunctive relief in august 2010 cordis filed an amended complaint to add an additional patent and in september 2010 we filed counterclaims of invalidity and noninfringement on october 26 2011 the district court granted cordis motion to add the promus element stent system to the case on february 6 2012 the district court granted our motion to stay the action until the conclusion of the reexaminations against the llanos patents that are pending in the us patent and trademark office on february 27 2015 the us patent and trademark office issued a decision in which certain claims of the llanos patent were deemed unpatentable on april 24 2015 cordis filed an appeal before the federal circuit on december 16 2015 the parties entered into a confidential settlement agreement on march 12 2010 we received a civil investigative demand cid from the civil division of the us department of justice doj requesting documents and information relating to reimbursement advice offered by us relating to certain crm devices on february 9 2016 the doj informed us that we are no longer required to retain documents and information relating to the cidon may 17 2010 dr luigi tellini filed suit against us and certain of our subsidiaries guidant italia srl and boston scientific spa in the civil tribunal in milan italy alleging certain of our cardiac rhythm management products infringe an italian patent  104the tellini patent owned by dr tellini and seeking monetary damages in january 2011 dr tellini refiled amended claims after his initial claims were dismissed without prejudice to refile on february 12 2015 the tribunal found the tellini patent invalid and dismissed the case on july 11 2014 we were served with a subpoena from the us attorney for the district of new jersey the subpoena seeks information relating to bridgepoint medical inc which we acquired in october 2012 including information relating to its sale of crossboss and stingray products educational and training activities that relate to those sales and our acquisition of bridgepoint medical on august 20 2015 the court unsealed a qui tam lawsuit brought by a former employee named robin levy against the company as well as a decision by the us attorney for new jersey declining to intervene in the lawsuit the lawsuit alleges that the company violated the federal and various state false claims acts through seeking to upcode chronic total occlusion cto procedures and requiring inpatient treatment and purchases of coronary stents in order for physicians to receive training on the cto procedure on january 26 2016 the court dismissed the qui tam lawsuiton october 14 2014 mk optics llc filed a complaint in the united states district court for the district of delaware alleging that the sale of our spyglass direct visualization system infringes a patent owned by mk optics the parties entered into a confidential settlement agreement and the case was dismissed on april 6 2015 on march 18 2015 denise fretter and maria korsgaard claiming to represent a class of current and former female field sales employees at boston scientific neuromodulation corporation bsnc filed a lawsuit against bsnc in the us district court for the central district of california the plaintiffs allege gender discrimination in pay promotions and differential treatment against them and the putative class on february 6 2016 the parties entered into a confidential settlement agreement and the case has been dismissednote l  stockholders equitypreferred stockwe are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers designations preferences and relative participating option or other rights thereof including dividend rights conversion rights voting rights redemption terms liquidation preferences and the number of shares constituting any series without any further vote or action by our stockholders as of december 31 2015 and 2014 we had no shares of preferred stock issued or outstandingcommon stockwe are authorized to issue 20 billion shares of common stock 001 par value per share holders of common stock are entitled to one vote per share holders of common stock are entitled to receive dividends if and when declared by the board of directors and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation holders of common stock have no preemptive subscription redemption or conversion rights the holders of common stock do not have cumulative voting rights the holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairson january 25 2013 our board of directors approved a stock repurchase program authorizing the repurchase of up to 10 billion of our common stock we did not repurchases any shares of our common stock during 2015 during 2014 we repurchased approximately 10 million shares of our common stock for 125 million during 2013 we repurchased approximately 51 million shares of our common stock for 500 million repurchased shares are available for reissuance under our equity incentive plans and for general corporate purposes including acquisitions as of december 31 2015 we had remaining 535 million authorized under our 2013 share repurchase program there were approximately 248 million shares in treasury as of december 31 2015 and december 31 2014note m  stock ownership plansemployee and director stock incentive plansin march and may 2011 our board of directors and stockholders respectively approved our 2011 longterm incentive plan the 2011 ltip authorizing up to 146 million shares of our common stock the 2011 ltip covers officers directors employees and consultants and provides for the grant of restricted or unrestricted common stock deferred stock units dsu options to acquire our common stock stock appreciation rights performance awards marketbased and performancebased dsus and other stock and nonstock awards shares reserved under our current and former stock incentive plans totaled approximately 163 million as of december 31 2015 the executive compensation and human resources committee of the board of directors consisting  105of independent nonemployee directors may authorize the issuance of common stock and authorize cash awards under the 2011 ltip in recognition of the achievement of longterm performance objectives established by the committeenonqualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date vest over a fouryear service period and have a tenyear contractual life in the case of qualified options if the recipient owns more than ten percent of the voting power of all classes of stock the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years nonvested stock awards including restricted stock awards and deferred stock units issued to employees are generally granted with an exercise price of zero and typically vest in five equal annual installments these awards represent our commitment to issue shares to recipients after the vesting period upon each vesting date such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipientthe following presents the impact of stockbased compensation on our consolidated statements of operations for the years ended december 31 2015 2014 and 2013  year ended december 31in millions except per share data 2015 2014 2013cost of products sold 7 6 8selling general and administrative expenses 81 79 79research and development expenses 19 18 18  107 103 105less income tax benefit 28 28 29  79 75 76       net impact per common share  basic 006 006 006net impact per common share  assuming dilution 006 006 006stock optionswe use the blackscholes optionpricing model to calculate the grantdate fair value of stock options granted to employees under our stock incentive plans we calculated the fair value for options granted during 2015 2014 and 2013 using the following estimated weightedaverage assumptions  year ended december 31  2015 2014 2013options granted in thousands 4441 4943 1992weightedaverage exercise price 1649 1302 744weightedaverage grantdate fair value 554 507 284blackscholes assumptions      expected volatility 31 37 36expected term in years weighted 60 60 59riskfree interest rate 149  192 169  209 089  172expected volatilitywe use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock optionsexpected termwe estimate the expected term of options using historical exercise and forfeiture data we believe that this historical data provides the best estimate of the expected term of new option grantsriskfree interest ratewe use yield rates on us treasury securities for a period approximating the expected term of the award to estimate the riskfree interest rate in our grantdate fair value assessment 106expected dividend yieldwe have not historically paid cash dividends to our stockholders and currently do not intend to pay cash dividends therefore we have assumed an expected dividend yield of zero in our grantdate fair value assessmentinformation related to stock options for 2015 2014 and 2013 under stock incentive plans is as follows  stock optionsin thousands weightedaverageexercise price weighted averageremainingcontractual life in years aggregateintrinsicvaluein millionsoutstanding as of december 31 2012 54881 12    granted 1992 7    exercised 7221 8    cancelledforfeited 4760 21    outstanding as of december 31 2013 44892 12    granted 4943 13    exercised 4418 8    cancelledforfeited 5909 17    outstanding as of december 31 2014 39508 11    granted 4441 16    exercised 9040 9    cancelledforfeited 3820 25    outstanding as of december 31 2015 31089 11 53 240exercisable as of december 31 2015 22104 10 40 196expected to vest as of december 31 2015 8299 13 84 42total vested and expected to vest as of december 31 2015 30403 11 52 238the total intrinsic value of stock options exercised was 69 million in 2015 and 24 million in both 2014 and 2013 107nonvested stockwe value restricted stock awards and dsus based on the closing trading value of our shares on the date of grant information related to nonvested stock awards during 2015 2014 and 2013 is as follows  nonvestedstock award unitsin thousands weighted averagegrant date fair valuebalance as of december 31 2012 36593 7granted 13913 8vested 1 10307 8forfeited 2860 7balance as of december 31 2013 37339 7granted 7072 13vested 1 11205 7forfeited 2671 8balance as of december 31 2014 30535 9granted 6606 16vested 1 11607 8forfeited 1770 10balance as of december 31 2015 23764 111the number of restricted stock units vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirementsthe total vesting date fair value of stock award units that vested was approximately 186 million in 2015 146 million in 2014 and 80 million in 2013marketbased dsu awardsduring 2015 2014 and 2013 we granted marketbased dsu awards to certain members of our senior management team the number of shares ultimately issued to the recipient is based on the total shareholder return tsr of our common stock as compared to the tsr of the common stock of the other companies in the sampp 500 health care index over a threeyear performance period in addition award recipients must remain employed by us throughout the threeyear performance period to attain the full amount of the marketbased dsus that satisfied the market performance criteriawe determined the fair value of the 2015 marketbased dsu awards to be approximately 7 million and the fair values of the 2014 and the 2013 marketbased awards to be approximately 6 million and 8 million respectively we determined these fair values based on monte carlo simulations as of the date of grant utilizing the following assumptions  2015 2014 2013  awards awards awardsstock price on date of grant 1631 1308 739measurement period in years 30 30 30riskfree rate 098 066 034we recognize the expense on these awards in our consolidated statements of operations on a straightline basis over the threeyear measurement periodfree cash flow performancebased dsu awardsduring 2015 2014 and 2013 we granted free cash flow performancebased dsu awards to certain members of our senior management team the attainment of these performancebased dsus is based on our adjusted free cash flow fcf measured against our internal annual financial plan performance for fcf fcf is measured over a oneyear performance period beginning january 1st of each year and ending december 31st the number of performancebased dsus as to which the performance criteria under this program shall be determined to have been satisfied will be in a range of 0 to 150 of the target number of performancebased dsus awarded to the participant in addition award recipients must remain employed by us throughout a threeyear service  108period inclusive of the oneyear performance period to attain the full amount of the performancebased dsus that satisfied the performance criteriawe determined the fair value of the 2015 fcf awards to be approximately 6 million based on the closing stock price at december 31 2015 and an achievement of approximately 104 of the target payout the per unit fair value is 1844 which is the closing stock price on december 31 2015 we determined the fair value of the 2014 fcf awards to be approximately 5 million and the per unit fair value was 1325 and we determined the fair value of the 2013 fcf awards to be approximately 9 million and the per unit fair value was 1202we recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grantexpense attributionwe recognize compensation expense for our stock using a straightline method over the substantive vesting period most of our stock awards provide for immediate vesting upon death or disability of the participant in addition our stock grants to employees provide for accelerated vesting of our stockbased awards other than performancebased and marketbased awards upon retirement in accordance with the terms of our stock grants for employees who will become retirement eligible prior to the vest date we expense stockbased awards other than performancebased and marketbased awards over the greater of one year or the period between grant date and retirementeligibility the performancebased and marketbased awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirementeligibilitywe recognize stockbased compensation expense for the value of the portion of awards that are ultimately expected to vest asc topic 718 compensation  stock compensation requires forfeitures to be estimated at the time of grant and revised if necessary in subsequent periods if actual forfeitures differ from those estimates the term forfeitures is distinct from cancellations or expirations and represents only the unvested portion of the surrendered stockbased award we have applied based on an analysis of our historical forfeitures a weightedaverage annual forfeiture rate of approximately nine percent to all unvested stockbased awards as of december 31 2015 which represents the portion that we expect will be forfeited each year over the vesting period we reevaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary ultimately we will only recognize expense for those shares that vestunrecognized compensation costwe expect to recognize the following future expense for awards outstanding as of december 31 2015   unrecognized compensation  costin millions1 weighted averageremaining vesting periodin yearsstock options 25  nonvested stock awards 135    160 131amounts presented represent compensation cost net of estimated forfeituresemployee stock purchase plansour global employee stock purchase plan provides for the granting of options to purchase up to 50 million shares of our common stock to all eligible employees under the global employee stock purchase plan we grant each eligible employee at the beginning of each sixmonth offering period an option to purchase shares of our common stock equal to not more than ten percent of the employees eligible compensation or the statutory limit under the us internal revenue code such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period whichever is less as of december 31 2015 there were approximately 17 million shares available for future issuance under the employee stock purchase planinformation related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows shares in thousands 2015 2014 2013shares issued or to be issued 2529 2618 3833range of purchase prices 1124  1513 1012  1104 501  796 109we use the blackscholes optionpricing model to calculate the grantdate fair value of shares issued under the employee stock purchase plan we recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period we recognized 9 million in expense associated with our employee stock purchase plan in 2015 8 million in 2014 and 7 million in 2013note n  weighted average shares outstanding  year ended december 31in millions 2015 2014 2013weighted average shares outstanding  basic 13412 13243 13412net effect of common stock equivalents   weighted average shares outstanding  assuming dilution 13412 13243 13412we generated net losses in 2015 2014 and 2013 our weightedaverage shares outstanding for earnings per share calculations excluded common stock equivalents of 22 million 24 million and 19 million due to our net loss positions in 2015 2014 and 2013 respectivelyweightedaverage shares outstanding assuming dilution also excludes the impact of 2 million stock options for 2015 12 million for 2014 and 16 million for 2013 due to the exercise prices of these stock options being greater than the average fair market value of our common stock during the yearnote o  segment reportingwe have three reportable segments comprised of cardiovascular rhythm management and medsurg which represent an aggregation of our operating segments each of our reportable segments generates revenues from the sale of medical devices we measure and evaluate our reportable segments based on segment net sales and operating income excluding the impact of changes in foreign currency and sales from divested businesses sales generated from reportable segments and divested businesses as well as operating results of reportable segments and corporate expenses are based on internallyderived standard currency exchange rates which may differ from year to year and do not include intersegment profits we exclude from segment operating income certain corporaterelated expenses and certain charges or credits that our chief operating decision maker considers to be nonrecurring andor nonoperational such as amounts related to goodwill and other intangible asset impairment charges acquisition divestiture restructuring and litigationrelated charges and credits pension termination charges and amortization expense although we exclude these amounts from segment operating income they are included in reported consolidated operating income loss and are included in the reconciliation below 110a reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying consolidated statements of operations is as follows  year ended december 31in millions 2015 2014 2013net sales      interventional cardiology 2242 2092 1995peripheral interventions 975 861 805cardiovascular 3217 2953 2800       cardiac rhythm management 1934 1922 1882electrophysiology 248 228 154rhythm management 2182 2150 2036       endoscopy 1422 1343 1277urology and pelvic health 735 542 505neuromodulation 512 474 454medsurg 2669 2359 2236net sales allocated to reportable segments 8068 7462 7072sales generated from business divestitures  4 58impact of foreign currency fluctuations 591 86 13  7477 7380 7143  year ended december 31in millions 2015 2014 2013depreciation expense      cardiovascular 116 120 111rhythm management 94 92 99medsurg 73 75 73depreciation expense allocated to reportable segments 283 287 283impact of foreign currency fluctuations 9  4  274 287 279  year ended december 31in millions 2015 2014 2013income loss before income taxes      cardiovascular 972 767 665rhythm management 328 289 211medsurg 856 746 679operating income allocated to reportable segments 2156 1802 1555corporate expenses and currency exchange 486 308 203goodwill and intangible asset impairment charges pension termination charges and acquisition divestiture litigation and restructuringrelated net charges 1502 1357 822amortization expense 495 438 410operating income loss 327 301 120other expense net 323 208 343  650 509 223 111  as of december 31in millions 2015 2014total assets   restatedcardiovascular 1583 1501rhythm management 1279 1329medsurg 1141 982total assets allocated to reportable segments 4003 3812goodwill 6473 5898other intangible assets net 6194 5606all other corporate assets 1463 1708  18133 17024certain prior year balances related to debt issuance costs have been restated to reflect our adoption of asc update no 201503 interestimputation of interest subtopic 83530 simplifying the presentation of debt issuance costs amounts reclassified from other longterm assets to longterm debt were not material please refer to note a  significant accounting policies and note q  new accounting pronouncements for additional details enterprisewide information based on actual currency exchange rates  year ended december 31in millions 2015 2014 2013net sales      interventional cardiology 2033 2057 1997cardiac rhythm management 1807 1912 1886endoscopy 1306 1323 1280peripheral interventions 904 850 809urology and pelvic health 693 535 505neuromodulation 501 472 453electrophysiology 233 227 155  7477 7376 7085sales generated from divested businesses  4 58  7477 7380 7143       united states 4229 3885 3743japan 602 678 744other countries 2646 2813 2598  7477 7376 7085sales generated from divested businesses  4 58  7477 7380 7143  as of december 31in millions 2015 2014 2013longlived assets      united states 1018 1002 998ireland 170 197 240other foreign countries 302 308 308property plant and equipment net 1490 1507 1546goodwill 6473 5898 5693other intangible assets net 6194 5606 5950  14157 13011 13189 112note p  changes in other comprehensive incomethe following table provides the reclassifications out of other comprehensive income for the years ended december 31 2015 and december 31 2014 amounts in the chart below are presented net of taxyear ended december 31 2015    in millionsforeign currency translation adjustmentsunrealized gainslosses on derivative financial instrumentsdefined benefit pension items  othertotalbeginning balance3821937144other comprehensive income loss before reclassifications1670351gainloss reclassified from accumulated other comprehensive income13730107net currentperiod other comprehensive income16672756ending balance541521088     year ended december 31 2014    in millionsforeign currency translation adjustmentsunrealized gainslosses on derivative financial instrumentsdefined benefit pension items  othertotalbeginning balance1614119106other comprehensive income loss before reclassifications2214510113gainloss reclassified from accumulated other comprehensive income67875net currentperiod other comprehensive income22781838ending balance3821937144the income tax impact of the amounts in other comprehensive income for unrealized gainslosses on derivative financial instruments before reclassifications was an expense of 39 million in the year ended december 31 2015 and an expense of 83 million in the year ended december 31 2014 the gains and losses on derivative financial instruments reclassified from accumulated other comprehensive income were reduced by income tax impacts of 78 million in the year ended december 31 2015 and 38 million in the year ended december 31 2014 refer to note e  fair value measurements for further detail on the reclassifications related to derivativesthe income tax impact of the amounts in other comprehensive income for defined benefit and pension items before reclassifications was a benefit of 2 million in the year ended december 31 2015 and a benefit of 5 million in the year ended december 31 2014 the gains and losses on defined benefit and pension items reclassified from accumulated other comprehensive income were reduced by income tax impacts of 17 million in the year ended december 31 2015 and 5 million in the year ended december 31 2014 note q  new accounting pronouncementsfrom time to time new accounting pronouncements are issued by the fasb or other standard setting bodies recently issued standards typically do not require adoption until a future effective date prior to their effective date we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statementsstandards implementedasc update no 201408in april 2014 the fasb issued asc update no 201408 presentation of financial statements topic 205 and property plant and equipment topic 360 reporting discontinued operations and disclosures of disposals of components of an entity update no 201408 changed the criteria for reporting discontinued operations and enhanced convergence of the fasbs and the international accounting standard boards iasb reporting requirements for discontinued operations we were required to apply  113this amendment prospectively to 1 all disposals or classifications as held for sale of components of an entity that occurred within annual periods beginning on or after december 15 2014 and interim periods within those years and 2 all businesses that on acquisition are classified as held for sale that occurred within annual periods beginning on or after december 15 2014 and interim periods within those years we adopted update no 201408 beginning in our first quarter ended march 31 2015 the adoption of update no 201408 did not impact our results of operations or financial position asc update no 201503in april 2015 the fasb issued asc update no 201503 interestimputation of interest subtopic 83530 simplifying the presentation of debt issuance costs update no 201503 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability consistent with debt discounts update no 201503 is effective for annual reporting periods beginning after december 15 2015 and interim periods within those reporting periods early adoption is permitted for financial statements that have not been previously issued we adopted update no 201503 as of december 31 2015 which required us to reclassify our debt issuance costs from deferred charges to direct deductions of our debt liabilities we were required to apply this amendment retrospectively to all prior periods reflected in the financial statement the adoption of update no 201503 did not have a material impact on our financial position and had no impact on our results of operations standards to be implementedasc update no 201409in may 2014 the fasb issued asc update no 201409 revenue from contracts with customers topic 606 update no 201409 provides enhancements to the quality and consistency of how revenue is reported while also improving comparability in the financial statements of companies using international financial reporting standards and us gaap the core principle requires entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services in july 2015 the fasb voted to approve a one year deferral making the standard effective for public entities for annual and interim periods beginning after december 15 2017 as such the standard will be effective for us on january 1 2018 under the deferral early application is still permitted but not before the original public organization effective date which is for annual reporting periods beginning after december 15 2016 we expect to adopt update no 201409 effective january 1 2018 we are in the process of determining the effect that the adoption of this standard will have on our financial position and results of operationsasc update no 201505in april 2015 the fasb issued asc update no 201505 intangibles goodwill and other  internal use software subtopic 35040 customers accounting for fees paid in a cloud computing arrangement update no 201505 provides accounting guidance on how customers should treat cloud computing arrangements if a cloud computing arrangement includes a software license then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses if a cloud computing arrangement does not include a software license the customer should account for the arrangement as a service contract update no 201505 is effective for annual reporting periods beginning after december 15 2015 and interim periods within those reporting periods we elected to adopt the amendments prospectively to all arrangements entered into or materially modified after the effective date  the adoption of update no 201505 is not expected to have a material impact on our financial position or results of operationsasc update no 201512in july 2015 the fasb issued asc update no 201512 plan accounting defined benefit pension plans topic 960 defined contribution pension plans topic 962 and health and welfare benefit plans topic 965 update no 201512 has three parts part i designates contract value as the only required measure for fully benefitresponsive investment contracts part ii simplifies the investment disclosure requirements under topics 820 960 962 and 965 for employee benefit plans and part iii provides an alternative measurement date for fiscal periods that do not coincide with a monthend date update no 201512 is effective for fiscal years beginning after december 15 2015 the adoption of update no 201512 is not expected to have a material impact on our financial position or results of operations asc update no 201516in september 2015 the fasb issued asc update no 201516 business combinations topic 805 simplifying the accounting for measurement  period adjustments update no 201516 eliminates the requirement to restate prior period financial statements  114for measurement period adjustments following a business combination update no 201516 requires that the cumulative impact of a measurement period adjustment including the impact on prior periods be recognized in the reporting period in which the adjustment is identified the prior period impact of the adjustment should be either presented separately on the face of the income statement or disclosed in the notes update no 201516 is effective for fiscal years beginning after december 15 2015 the adoption of update no 201516 is not expected to have a material impact on our financial position or results of operationsasc update no 201517in november 2015 the fasb issued asc update no 201517 income taxes topic 740 update no 201517 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position it is effective for fiscal years beginning after december 15 2016 and interim periods within those annual periods earlier application is permitted an entity can elect to adopt prospectively or retrospectively the adoption of update no 201517 will not impact our results of operations we are in the process of determining the effect that the adoption of this standard will have on our financial positionasc update no 201601in january 2016 the fasb issued asc update no 201601 financial instrumentsoverall subtopic 82510 recognition and measurement of financial assets and financial liabilities it is effective for fiscal years beginning after december 15 2017 including interim periods within those fiscal years early application of certain provisions is permitted update 201601 requires entities to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair value with changes recognized in net income however an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment if any plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer it also simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment update 201601 also requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset and liability the adoption of update no 201601 is not expected to have a material impact on our financial position or results of operationsno other new accounting pronouncements issued or effective during the period had or is expected to have a material impact on our consolidated financial statements 115quarterly results of operationsin millions except per share dataunaudited  three months ended  mar 31 june 30 sept 30 dec 312015        net sales 1768 1843 1888 1978gross profit 1248 1303 1349 1405operating income loss 24 219 299 271net income loss 1 102 198 142net income loss per common share  basic 000 008 015 011net income loss per common share  assuming dilution 000 008 015 011         2014        net sales 1774 1873 1846 1887gross profit 1237 1310 1296 1327operating income loss 197 69 64 493net income loss 133 4 43 299net income loss per common share  basic 010 000 003 023net income loss per common share  assuming dilution 010 000 003 023our reported results for 2015 included intangible asset impairment charges pension termination charges debt extinguishment charges restructuring and restructuring related charges litigationrelated net charges acquisition and divestiturerelated net charges discrete tax items and amortization expense after tax of 287 million in the first quarter 192 million in the second quarter 524 million in the third quarter and 504 million in the fourth quarter these aftertax net charges consisted primarily of 705 million of litigationrelated net charges and 446 million of amortization expenseour reported results for 2014 included intangible asset impairment charges restructuring and restructuring related charges litigationrelated net charges acquisition and divestiturerelated net credits discrete tax items and amortization expense after tax of 135 million in the first quarter 281 million in the second quarter 230 million in the third quarter and 602 million in the fourth quarter these aftertax net charges consisted primarily of 659 million of litigationrelated net charges and 385 million of amortization expense 116